CN103087077B - Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically - Google Patents
Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically Download PDFInfo
- Publication number
- CN103087077B CN103087077B CN201110342682.0A CN201110342682A CN103087077B CN 103087077 B CN103087077 B CN 103087077B CN 201110342682 A CN201110342682 A CN 201110342682A CN 103087077 B CN103087077 B CN 103087077B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- room temperature
- piperazine
- egfr
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 150000002240 furans Chemical class 0.000 title claims abstract description 24
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract description 36
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract description 35
- 108091008605 VEGF receptors Proteins 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 239000002870 angiogenesis inducing agent Substances 0.000 claims abstract description 12
- 239000003112 inhibitor Substances 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract description 4
- -1 inorganic acid salt Chemical class 0.000 claims description 64
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003368 amide group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 150000001721 carbon Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 206010027476 Metastases Diseases 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 229940121647 egfr inhibitor Drugs 0.000 claims description 3
- 230000029052 metamorphosis Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 238000013507 mapping Methods 0.000 claims description 2
- 150000005451 methyl sulfates Chemical class 0.000 claims description 2
- 229950000081 metilsulfate Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 229940001468 citrate Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 238000002965 ELISA Methods 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000013459 approach Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 138
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 86
- 238000005406 washing Methods 0.000 description 73
- 230000002829 reductive effect Effects 0.000 description 67
- 239000012074 organic phase Substances 0.000 description 66
- 238000012544 monitoring process Methods 0.000 description 64
- 239000007787 solid Substances 0.000 description 62
- 239000002994 raw material Substances 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 57
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 57
- 238000000605 extraction Methods 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 53
- 238000005160 1H NMR spectroscopy Methods 0.000 description 52
- 238000003756 stirring Methods 0.000 description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 47
- 238000010898 silica gel chromatography Methods 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 45
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 43
- 238000001035 drying Methods 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 235000002639 sodium chloride Nutrition 0.000 description 39
- 229920006395 saturated elastomer Polymers 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000011780 sodium chloride Substances 0.000 description 29
- 229910000029 sodium carbonate Inorganic materials 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 24
- 239000000376 reactant Substances 0.000 description 24
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 21
- 229910052796 boron Inorganic materials 0.000 description 21
- 238000010792 warming Methods 0.000 description 20
- 241000790917 Dioxys <bee> Species 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 239000004327 boric acid Substances 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000012280 lithium aluminium hydride Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 9
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 8
- 229960002584 gefitinib Drugs 0.000 description 8
- UIGXGNUMMVHJKX-UHFFFAOYSA-N (4-formylphenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(C=O)C=C1 UIGXGNUMMVHJKX-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- OYMCMWPHMPODNK-UHFFFAOYSA-N 2-bromofuran Chemical class BrC1=CC=CO1 OYMCMWPHMPODNK-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 125000005251 aryl acyl group Chemical group 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 125000002541 furyl group Chemical class 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- QHTPSODXPLCXJB-UHFFFAOYSA-N piperazine;urea Chemical compound NC(N)=O.C1CNCCN1 QHTPSODXPLCXJB-UHFFFAOYSA-N 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- YQBQXVOYLBLFBM-XMMPIXPASA-N (2S)-2-[[6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]thieno[3,2-d]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2SC3=C(N[C@H](CO)C=4C=CC=CC=4)N=CN=C3C=2)C=C1 YQBQXVOYLBLFBM-XMMPIXPASA-N 0.000 description 3
- ZGABDPXDUGYGQE-UHFFFAOYSA-N 1-piperidin-1-ylpiperazine Chemical compound C1CCCCN1N1CCNCC1 ZGABDPXDUGYGQE-UHFFFAOYSA-N 0.000 description 3
- DMXXYTGIEQSMCO-UHFFFAOYSA-N 2-bromo-4-chlorothiophene Chemical compound ClC1=CSC(Br)=C1 DMXXYTGIEQSMCO-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001544 thienyl group Chemical class 0.000 description 3
- BODNONDEEOBWFP-AREMUKBSSA-N (2S)-2-[[6-[4-[[4-(cyclopropylmethyl)piperazin-1-yl]methyl]phenyl]thieno[2,3-d]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1SC=2C(C=C1)=CC=C1CN(CC1)CCN1CC1CC1 BODNONDEEOBWFP-AREMUKBSSA-N 0.000 description 2
- QUNHMYPDQCZYKA-JOCHJYFZSA-N (2s)-2-phenyl-2-[[6-[4-(piperazin-1-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-4-yl]amino]ethanol Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C=1S2)=NC=NC=1C=C2C(C=C1)=CC=C1CN1CCNCC1 QUNHMYPDQCZYKA-JOCHJYFZSA-N 0.000 description 2
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- HPGZFAJHGNAUNQ-UHFFFAOYSA-N 1-morpholin-4-yl-1-piperazin-1-ylurea Chemical compound N1(CCOCC1)N(C(=O)N)N1CCNCC1 HPGZFAJHGNAUNQ-UHFFFAOYSA-N 0.000 description 2
- DFTNCGRDYHINDS-UHFFFAOYSA-N 3-bromo-2-methylthiophene Chemical compound CC=1SC=CC=1Br DFTNCGRDYHINDS-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- FDARTJCIFLZHFJ-UHFFFAOYSA-N CN(CC1)CCN1C(N1CCNCC1)=O Chemical compound CN(CC1)CCN1C(N1CCNCC1)=O FDARTJCIFLZHFJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005257 alkyl acyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229950002366 nafoxidine Drugs 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229940005654 nitrite ion Drugs 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- KAEGEKMFVUAPSY-UHFFFAOYSA-N piperazin-1-ylurea Chemical compound NC(=O)NN1CCNCC1 KAEGEKMFVUAPSY-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- JBFBFCTUNDSIRH-UHFFFAOYSA-N (2-formylphenoxy)boronic acid Chemical compound OB(O)OC1=CC=CC=C1C=O JBFBFCTUNDSIRH-UHFFFAOYSA-N 0.000 description 1
- AYSUBAPTVMHHDG-JOCHJYFZSA-N (2s)-2-phenyl-2-[[6-[4-(piperazin-1-ylmethyl)phenyl]thieno[2,3-d]pyrimidin-4-yl]amino]ethanol Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1SC=2C(C=C1)=CC=C1CN1CCNCC1 AYSUBAPTVMHHDG-JOCHJYFZSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 0 *Brc1cc(ncnc2N[C@](CO)c3ccccc3)c2[s]1 Chemical compound *Brc1cc(ncnc2N[C@](CO)c3ccccc3)c2[s]1 0.000 description 1
- IVLIBVDZIYFXBZ-UHFFFAOYSA-N 1-(cyclopropylmethyl)piperazine Chemical compound C1CNCCN1CC1CC1 IVLIBVDZIYFXBZ-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XXKGMXBJIMBFCS-WAYWQWQTSA-N CC/N=C\N(C)C Chemical compound CC/N=C\N(C)C XXKGMXBJIMBFCS-WAYWQWQTSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- UZVDFSBVOXUSDV-UHFFFAOYSA-N CN(CC1)CCN1C(N1CCN(Cc2ccc(B(O)O)cc2)CC1)=O Chemical compound CN(CC1)CCN1C(N1CCN(Cc2ccc(B(O)O)cc2)CC1)=O UZVDFSBVOXUSDV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- IJXJGQCXFSSHNL-MRVPVSSYSA-N N[C@H](CO)c1ccccc1 Chemical compound N[C@H](CO)c1ccccc1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 description 1
- VXWBQOJISHAKKM-UHFFFAOYSA-N OB(c1ccc(C=O)cc1)O Chemical compound OB(c1ccc(C=O)cc1)O VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
- CYMXTKNOROVINH-UHFFFAOYSA-N OC(C)(C)C(C)(C)O.C1(=CC=CC=C1)OB(O)O Chemical compound OC(C)(C)C(C)(C)O.C1(=CC=CC=C1)OB(O)O CYMXTKNOROVINH-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- KIALFUYSJAAJSU-UHFFFAOYSA-N cyclopropyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CC1 KIALFUYSJAAJSU-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- FMLPQHJYUZTHQS-UHFFFAOYSA-N tert-butyl 3-methylpiperazine-1-carboxylate Chemical compound CC1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention discloses a kind of Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically. Described derivative is the compound with general formula I, general formula I I, general formula III or general formula I V:
Description
Technical field
The present invention relates to miazines derivative and its preparation method and application, specifically, relate to one and there is epidermal growthFactor acceptor EGFR and/or Angiogenesis factor receptors VEGFR suppress active Thienopyrimidine and furans miazines and spread outBiological, its preparation method and in application pharmaceutically, belongs to pharmaceutical chemistry technical field.
Background technology
Tumour is one of serious disease threatening human health, and its treatment mainly comprises radiotherapy, chemotherapy and operative treatment. CloselyOver year, along with the development of cell biology and tumor pharmacology, there is huge change in the chemotherapy of tumour. TraditionalThereby chemotherapeutic agent also causes that owing to non-specifically blocking cell division normal cell is dead in killing tumour cellDie and abandoned gradually, meanwhile, using the key node albumen in the signal path of abnormal activation in tumour cell as target spot,The micromolecular inhibitor of finding efficient, low toxicity, high specificity has become the important directions of current antineoplastic research and development.In tumour unconventionality expression activate receptor tyrosine kinase (RTK) due to tumor development, invasion and attack shift, chemotherapy resistanceAll bring into play key effect and become the focus of antineoplastic research Deng links.
EGF-R ELISA (EGFR, epidermalgrowthfactorreceptor claim again HER1 or cerbB1) isIn human cancer, express EGFR-TK HER family member the most widely. EGFR structure comprises three regions: extracellular region,Cross-film district and intracellular region. The amino terminal of extracellular region is made up of 622 amino acid, has 2 of formation ligand binding domain to be rich inCysteine section; Cross-film district is a single α spiral; Intracellular region comprises kinases district and has many Tyr phosphorylation sitesCarboxyl terminal afterbody. EGFR-TK (RTK) is that the γ phosphate transfection of ATP is transported to tyrosine residue. Tying with partAfter closing, there is homology or heterodimer and make TK region form tight connection in EGFR. At carboxyl terminal afterbody RTKMediation Tyr phosphorylation site carries out phosphorylation, created enzyme and connect sub-albumen binding site (Y992, Y1068,Y1086, Y1148 and Y11730), thereby can start Cellular Signaling Transduction Mediated reaction. The conduction of these signals forms different thinBorn of the same parents' reaction, comprises propagation, differentiation, adhesion and vascularization, shifts and apoptosis inhibit.
Research shows, EGFR is at non-small cell lung cancer, prostate cancer, breast cancer, colorectal cancer, head and neck cancer, cancer of the stomach, ovaryIn cancer and cancer of pancreas, have expression, EGFR activation causes sophisticated signal conduction reaction. In dissimilar solid tumor, EGFRThere are propagation and overexpression, cause downstream signal conduction out of control and cause the formation of various tumours. ATP-binding site in EGFRSudden change affect the RTK activity of acceptor, disturb the formation of tumorigenesis signal, meanwhile, EGFR also with progress and the poor prognosis of tumourClosely related.
The unique effect in tumorigenesis due to EGFR and VEGFR, its monoclonal antibody and micromolecular inhibitor becomeThe focus of targeting antineoplastic medicine thing research and development. At present, there is the inhibitor listing of several targeting EGFRs or VEGFR, near20 drug candidates are in clinical each development. Wherein, Gefitinib and Erlotinib representative listing target earlyThe micromolecular inhibitor of EGFR. Gefitinib (Gefitinib claims again ZD1839 or Iressa) is as three line single therapy medicinesFor advanced Non-small cell lung (nonsmallcelllungcancer, NSCLC). (Erlotinib claims again OSI774 to ErlotinibOr Tarceva) two wires or the three line medicines of the advanced NSCLC of failing to respond to any medical treatment as standard scheme.
But, along with the clinical practice of these medicines, it is found that not to be that all high expressed EGFR patients can be to these medicinesThing is effective, and some tumour that initially Gefitinib (Gefitinib) is had to a therapeutic response occurs again that after treatment some months disease entersExhibition. These results show, the EGFR inhibitor antineoplastic using at present has natural or Secondary cases resistance phenomenon, because ofThis, Development of Novel has low drug resistance and maybe can alleviate the medicine of early stage inhibitor drug resistance and become tyrosine kinase inhibitorNew development direction.
Summary of the invention
For the existing the problems referred to above of prior art, the object of this invention is to provide one and there is EGF-R ELISAEGFR and/or Angiogenesis factor receptors VEGFR suppress active Thienopyrimidine and furans miazines derivative, its systemPreparation Method and in application pharmaceutically.
Thienopyrimidine provided by the invention and furans miazines derivative, be have general formula I, general formula I I, general formula III orThe compound of general formula I V:
In above-mentioned general formula:
X is oxygen or sulphur; Z is nitrogen or carbon;
R is hydrogen, containing the alkyl of 1～6 carbon atom or the alkyl of replacement, containing the alkyl acyl of 1～6 carbon atom, containing 3～6The cycloalkyl acyl group of individual carbon atom, containing the alkene acyl group of 2～6 carbon atoms or alkene acyl group, aryl-acyl or the replacement of replacementThe reverse amide groups of amide groups, reverse amide groups or replacement of aryl-acyl, sulfonyl, amide groups or replacement in arbitrarilyA kind of;
Ar1 be phenyl, 2 or 3-fluorine substituted-phenyl, 2 or 3-trifluoromethyl substituted-phenyl, 2 or 3-chlorine substituted-phenyl, 2 or3-itrile group substituted-phenyl, 2-or 3-C1-3Alkyl-substituted phenyl, thienyl, 3-C1-3Thienyl, furyl that alkyl replaces,3-C1-3 alkyl replace furyl, 2 or 3-pyridine radicals in any one;
Ar2For phenyl, the C of phenyl, halogen replacement1-6Xenyl, naphthalene that phenyl, xenyl, the halogen that alkyl replaces replacesThienyl, C that base, pyridine radicals, thienyl, halogen replace1-3The furan that thienyl, furyl, the halogen that alkyl replaces replacesBase, C mutter1-3Any one in the furyl that alkyl replaces.
Further, described Thienopyrimidine and furans miazines derivative, be have general formula I, general formula I I, general formula III orThe compound of general formula I V, and in general formula: X is oxygen or sulphur; Z is nitrogen; Ar1For phenyl; Ar2For phenyl; R is hydrogen, containsThe alkyl of 1～6 carbon atom or the alkyl of replacement, containing the alkyl acyl of 1～6 carbon atom, containing the cycloalkyl of 3～6 carbon atomsAcyl group, containing aryl-acyl, the sulphonyl of the alkene acyl group of 2～6 carbon atoms or alkene acyl group, aryl-acyl or the replacement of replacementAny one in the reverse amide groups of the amide groups of base, amide groups or replacement, reverse amide groups or replacement.
The preparation method of the Thienopyrimidine that general formula I provided by the invention represents and furans miazines derivative, comprises as followsStep 3. or step 1. and 3. step 2. and 3. or step 1.～3.:
The Thienopyrimidine that general formula I I provided by the invention represents and the preparation method of furans miazines derivative, comprise as followsStep 5. or step 2. and 5. step 4. and 5. or step 2. and 4. and 5.:
The preparation method of the Thienopyrimidine that general formula III provided by the invention represents and furans miazines derivative, comprises as followsStep 7. or step 1. and 7. step 6. and 7. or step 1. and 6. and 7.:
The Thienopyrimidine that general formula I V provided by the invention represents and the preparation method of furans miazines derivative, comprise as followsStep 8. or step 4. and 8. step 6. and 8. or step 4. and 6. and 8.:
Further, described general formula I I represents Thienopyrimidine and furans miazines derivative can also be represented by general formula IThienopyrimidine and furans miazines derivative carry out hydrogenation and obtain.
Further, described general formula I V represents Thienopyrimidine and furans miazines derivative can also be represented by general formula IIIThienopyrimidine and furans miazines derivative carry out hydrogenation and obtain.
Because research shows that Thienopyrimidine of the present invention and furans miazines derivative have EGF-R ELISA(EGFR) and/or the inhibition activity of Angiogenesis factor receptors (VEGFR), therefore, thieno of the present invention is phoneticThe dynamic isomer of pyridine and furans miazines derivative or described derivative, racemic modification, enantiomter, non-mapping are differentThe mixture of any one or a few in structure body, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, can answerFor the preparation of tyrosine kinase inhibitor, especially can be applicable to prepare EGFR and/or VEGFR inhibitor.
Furtherly, described inhibitor can be applicable to prepare prevention or treatment and EGF-R ELISA EGFR and/or bloodThe medicine of pipe growth factor receptors VEGFR relevant disease, specifically, can be applicable to prepare prevention or treatment and epidermal growth factorAbnormal cell proliferation, metamorphosis, motor function that sub-Receptor EGFR and/or Angiogenesis factor receptors VEGFR are relevantThe medicine of hyperfunction, angiogenesis and metastases disease.
Furtherly, described inhibitor can be applicable to prepare treatment or prevention and EGF-R ELISA EGFR and/Or the medicine of the relevant growth and metastasis of tumours of Angiogenesis factor receptors VEGFR.
Furtherly, the active component of described inhibitor preferably compound shown in table 1 or shown in the tautomerism of compoundBody, racemic modification, enantiomter, diastereoisomer, pharmaceutically acceptable salt, pharmaceutically acceptable solvent closeThe mixture of any one or a few in thing:
Table 1
Described pharmaceutically acceptable salt comprises without limitation: inorganic acid salt, example hydrochloric acid salt, hydrobromate, nitrate,Sulfate, phosphate etc.; Acylate, as formates, acetate, propionate, benzoate, maleate, rich horseHydrochlorate, succinate, tartrate, citrate etc.; Alkylsulfonate, as metilsulfate, ethyl sulfonate etc.;Arylsulphonate, as benzene sulfonate, tosilate etc.
Described pharmaceutically acceptable solvate comprise without limitation described compound and water, ethanol, isopropyl alcohol,The solvate of ether, acetone etc.
Compared with prior art, the novel structure of Thienopyrimidine provided by the invention and furans miazines derivative, hasIt is active that significantly EGFR inhibition activity, and part of compounds also has obvious inhibition to VEGFR, is expected to be developed as tyrosineKinases EGFR is or/and VEGFR inhibitor, raw for the preparation of prevention or treatment and EGF-R ELISA EGFR and/or blood vesselRelevant disease and and the blood vessels such as abnormal cell proliferation, metamorphosis and hypoerkinesia that growth factor receptor body VEGFR is relevantThe medicine of new life or metastases relevant disease, is especially expected for the preparation for the treatment of or prevention and EGF-R ELISA EGFRAnd/or the medicine of the relevant growth and metastasis of tumours of Angiogenesis factor receptors VEGFR, for Development of Novel have low drug resistance orCan alleviate early stage inhibitor drug resistance tyrosine kinase inhibitor drug provision new developmental direction and approach, have wideApplication prospect and medical value.
Detailed description of the invention
Further set forth the present invention below in conjunction with specific embodiment. Following embodiment is only interpreted as for the present invention is described notFor limiting the scope of the invention. After having read the content of the present invention's record, those skilled in the art can be rightThe present invention makes various changes or modifications, and these equivalences change and modification falls into the claims in the present invention book limited range equally.
In following embodiment the structure of prepared compound be by nuclear magnetic resonance (1HNMR) and mass spectrum (MS) giveDetermine.
1HNMR displacement (δ) with 1,000,000/unit (ppm) provides.1The mensuration of HNMR is to useBrukerAVANCE-400 nuclear magnetic resonance spectrometer, the solvent of mensuration is deuterated dimethyl sulfoxide (DMSO-d6), deuterochloroform (CDCl3)，Inside be designated as tetramethylsilane (TMS), chemical shift is with 10-6Provide as unit.
The mensuration of MS is by FINNIGANLCQAd (ESI) mass spectrograph (manufacturer: Therm, model: FinniganLCQadvantageMAX)。
The mensuration of IC50 value is with NovoStar ELIASA (German BMG company).
Thin layer silica gel is to use Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica gel plate.
Silica gel column chromatography is that use Yantai Huanghai Sea silica gel 200～300 order silica gel are carrier.
HPLC test be use Agilent 1200DAD high pressure liquid chromatograph (SunfireC18150 × 4.6mm chromatographic column) andWaters2695-2996 high pressure liquid chromatograph (GiminiC18150 × 4.6mm chromatographic column).
Microwave reaction is to use CEMDiscover-S908860 type microwave reactor.
In addition, in following examples, without specified otherwise, reaction is all carried out under blanket of nitrogen.
Argon atmospher refers to that reaction bulb connects the argon gas balloon of an about 1L volume.
Nitrogen atmosphere refers to that reaction bulb connects the hydrogen balloon of an about 1L volume.
In following examples, without specified otherwise, the solution in reaction refers to the aqueous solution.
Embodiment 1: preparation Compound I-1 and Compound I I-1
The first step:
Under room temperature, will be dissolved in carrene (10ml, 0.16mol) to carboxyl phenyl boric acid pinacol ester (1g, 4.03mmol)And in DMF (1ml, 13.0mmol), add NEP (0.6ml, 4.8mmol), and successivelyAdd 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (0.93g, 4.8mmol), N-hydroxy benzo triazole(0.66g, 4.8mmol), triethylamine (0.84ml, 6.04mmol), stirring at room temperature reaction is until TLC monitoring raw material reactionCompletely, in reactant liquor, add 10ml water, stir 30 minutes, with carrene (50ml*3) extraction, then use saturated chlorineChange sodium solution (50ml*2) washing, organic phase anhydrous magnesium sulfate drying, filters, and reduced pressure concentration, obtains: (4-ethyl-piperazinePiperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (1.4g, faint yellow solid), directlyFor next step reaction.
Second step:
Wherein the bromo-4-chlorothiophene of 6-[2,3-d] pyrimidine is according to method preparation described in patent WO2007/059257.
Under room temperature by bromo-compound 6-4-chlorothiophene [2,3-d] pyrimidine (1g, 4.0mmol) and L-benzene glycinol (1g, 7.2mmol)Be dissolved in DMF (20ml, 0.259mol), drip 1ml triethylamine (363mg, 7.19mmol),Stirring at room temperature, until TLC monitoring raw material reaction is complete, adds 200ml water, decompress filter, and filter cake washes (100ml*2) with waterObtain: compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (1.3g, faint yellow solid), productive rate:93％。
MSm/z(ESI)：351[M+1]。
1HNMR(400MHz，DMSO-d6)：8.24(s，1H)，8.16(d，J＝8.1Hz，1H)，8.02(s，1H)，7.38-7.40(m，2H)，7.23-7.32(m，2H)，7，20-7.22(m，1H)，5.39(m，1H)，4.98(t，J＝8.1Hz，1H)，3.71(m，2H)。
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (500mg, 1.43mmol) and (4-Ethyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (982mg, 2.86mmol)Be dissolved in DMF (15ml, 0.194mol), add successively tetra-triphenylphosphine palladium (164mg, 0.143mmol),Sodium carbonate liquor (1mol/L, 2.8ml), nitrogen protection, is heated to 80 DEG C until TLC monitoring raw material reaction is complete, naturally coldBut add water (100ml*3) washing to room temperature, with ethyl acetate (250ml*1) extraction, organic phase saturated aqueous common salt(100ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, and reduced pressure concentration, obtains: (S)-(4-ethyl-piperazine-1-yl)-4-[4-(2-hydroxyl-1-phenyl-ethamine)-thieno [2,3-d] pyrimidine-6-yl]-phenyl }-ketone (I-1) (440mg,Faint yellow solid), productive rate: 63%.
MSm/z(ESI)：487[M+1]。
1HNMR(400Hz，DMSO-d6)：8.30(d，2H)，8.19(d，1H)，7.79(d，2H)，7.51-7.20(m，7H)，5.46(m，1H)，5.01(t，，1H)，3.75(m，2H)，3.55(m，4H)，2.35(m，6H)，0.99(t，J＝8.0Hz，3H)。
The 4th step:
Under room temperature, Lithium Aluminium Hydride (27.3mg, 0.718mmol) and anhydrous tetrahydro furan (8ml, 98.63mmol) are mixedStir, to the oxolane (10ml, 0.123mol) that drips Compound I-1 (140mg, 0.287mmol) in reactant liquorSolution, stirring at room temperature reaction 1 hour, is warming up to 50 DEG C of reactions until TLC monitoring raw material reaction is complete, naturally cools to chamberTemperature adds 20ml water in reactant liquor, with ethyl acetate (100ml*3) extraction, then uses saturated nacl aqueous solution (100ml*2)Washing, the organic phase obtaining is filtered with anhydrous magnesium sulfate drying, and reduced pressure concentration is purified gained residue with silica gel column chromatography,Obtain: (S)-2-{6-[4-(4-ethyl-piperazine-1-ylmethyl)-phenyl]-thieno [2,3-d] pyrimidine-4-yl amino }-2-phenyl-ethanol(II-1) (15mg, faint yellow solid), productive rate: 11.0%.
MSm/z(ESI)：473[M+1]。
1HNMR(400Hz，DMSO-d6)：8.23-8.18(m，3H)，7.66(d，2H)，7.42-7.23(m，7H)，5.44(m，1H)，5.03(t，，1H)，3.76(m，2H)，3.55(m，6H)，2.41(m，6H)，0.98(t，，3H)。
Embodiment 2: preparation Compound I-2 and Compound I I-2
The first step:
Under room temperature, will be dissolved in carrene (27ml, 0.422mol) to carboxyl phenyl boric acid pinacol ester (3g, 12.10mmol)And in DMF (9ml, 0.116mol), add N methyl piperazine (1.45g, 14.5mmol), and successivelyAdd 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (2.79g, 14.4mmol), N-hydroxy benzo three nitrogenAzoles (1.98g, 12.9mmol), triethylamine (2.5ml, 17.99mmol), stirring at room temperature reaction is until TLC monitoring raw material is anti-Should be complete, in reactant liquor, add 30ml water, stir 30 minutes, with carrene (100ml*3) extraction, then use saturatedSodium chloride solution (100ml*2) washing, organic phase anhydrous magnesium sulfate drying, filters, and reduced pressure concentration, obtains: (4-firstBase-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (1.5g, whiteSolid), productive rate: 37.6%
Second step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl l-ethanol (100mg, 0.2857mmol)(4-methyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone(188mg, 0.5714mmol) is dissolved in DMF (4ml, 51.7mmol), adds successively four triphensBase phosphine palladium (33mg, 0.0286mmol), sodium carbonate liquor (1mol/L, 0.6ml), nitrogen protection, be heated to 80 DEG C untilTLC monitoring raw material reaction is complete, naturally cools to room temperature and adds water (100ml*3) washing, with ethyl acetate (250ml*1)Extraction, saturated aqueous common salt for organic phase (100ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, and subtractsPress concentratedly, purify gained residue with silica gel column chromatography, obtain: (S)-{ 4-[4-(2-hydroxyl-1-phenyl-ethamine)-thieno[2,3-d] pyrimidine-6-yl]-phenyl }-(4-methyl-piperazine-1-yl)-ketone (I-2) (71mg, white solid), productive rate: 52.6%.
MSm/z(ESI)：474[M+1]。
1HNMR(400Hz，DMSO-d6)：8.30(d，2H)，8.19(d，1H)，7.75(d，2H)，7.51-7.21(m，7H)，5.46(m，1H)，5.02(t，，1H)，3.75(m，2H)，3.55(m，4H)，2.35(m，4H)，2.19(s，3H)。
The 3rd step:
Under room temperature, Lithium Aluminium Hydride (100mg, 2.640mmol) and anhydrous tetrahydro furan (10ml, 0.123mol) mixing are stirredMix, molten to the oxolane (10ml, 0.123mol) that drips Compound I-2 (500mg, 1.056mmol) in reactant liquorLiquid, stirring at room temperature reaction 1 hour, is warming up to 50 DEG C of reactions until TLC monitoring raw material reaction is complete, naturally cools to room temperature,In reactant liquor, add 20ml water, with ethyl acetate (100ml*3) extraction, then use saturated nacl aqueous solution (100ml*2)Washing, the organic phase obtaining is filtered with anhydrous magnesium sulfate drying, and reduced pressure concentration is purified gained residue with silica gel column chromatography,Obtain: (S)-2-{6-[4-(4-methyl-piperazine-1-ylmethyl)-phenyl]-thieno [2,3-d] pyrimidine-4-yl amino }-2-phenyl-ethanol(II-2) (42mg, faint yellow solid), productive rate: 8.7%.
MSm/z(ESI)：460[M+1]。
1HNMR(400Hz，DMSO-d6)：8.30(d，2H)，8.19(d，1H)，7.75(d，2H)，7.51-7.21(m，7H)，5.46(m，1H)，5.02(t，，1H)，3.75(m，2H)，3.55(m，6H)，2.35(m，4H)，2.19(s，3H)。
Embodiment 3: preparation Compound I-3 and Compound I I-3
The first step:
Under room temperature, will be dissolved in carrene (27ml, 0.422mol) to carboxyl phenyl boric acid pinacol ester (3g, 12.10mmol)And in DMF (9ml, 0.116mol), add 1-cyclopropyl methyl piperazine (2.3g, 14.9mmol),And add successively 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (2.79g, 14.4mmol), N-hydroxy benzenesAnd triazole (1.98g, 12.9mmol), triethylamine (2.5ml, 17.99mmol), stirring at room temperature reaction is until TLC monitoringRaw material reaction is complete, in reactant liquor, adds 30ml water, stir 30 minutes, and with carrene (100ml*3) extraction, thenWith saturated nacl aqueous solution (100ml*2) washing, organic phase anhydrous magnesium sulfate drying, filters, and reduced pressure concentration, obtains:(4-cyclopropyl carbonyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone(3.5g, white solid), productive rate 61.4%, is used as next step reaction.
Second step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl l-ethanol (500mg, 1.43mmol) and(4-cyclopropyl carbonyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone(1.099g, 2.86mmol) is dissolved in DMF (15ml, 0.194mol), adds successively four triphenylsPhosphine palladium (164mg, 0.143mmol), sodium carbonate liquor (1mol/L, 2.8ml), nitrogen protection, is heated to 80 DEG C until TLCMonitoring raw material reaction is complete, naturally cools to room temperature and adds water (100ml*3) washing, by ethyl acetate (250ml*1) extractionGet, saturated aqueous common salt for organic phase (100ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, decompressionConcentrated, purify gained residue with silica gel column chromatography, obtain: (S)-(4-cyclopropyl methyl-piperazine-1-yl)-{ 4-[4-(2-hydroxylBase-1-phenyl-ethamine)-thieno [2,3-d] pyrimidine-6-yl]-phenyl }-ketone (I-3) (300mg, faint yellow solid), productive rate:60％。
MSm/z(ESI)：528[M+1]。
1HNMR(400Hz，DMSO-d6)：1HNMR(400Hz，DMSO-d6)：8.44m，2H)，8.26(s，1H)，7.75(d，2H)，7.52-7.28(m，7H)，5.48(m，1H)，5.20(t，1H)，3.87(m，1H)，3.68(s，2H)，3.09(m，8H)，1.23(m，1H)，0.68(m，2H)，0.44(m，2H)。
The 3rd step:
Under room temperature, Lithium Aluminium Hydride (90mg, 2.369mmol) and anhydrous tetrahydro furan (10ml, 0.123mol) mixing are stirredMix, molten to the oxolane (10ml, 0.123mol) that drips Compound I-3 (250mg, 0.474mmol) in reactant liquorLiquid, stirring at room temperature reaction 1 hour, is warming up to 50 DEG C of reactions until TLC monitoring raw material reaction is complete, naturally cools to room temperature,In reactant liquor, add 20ml water, with ethyl acetate (100ml*3) extraction, then use saturated nacl aqueous solution (100ml*2)Washing, the organic phase obtaining is filtered with anhydrous magnesium sulfate drying, and reduced pressure concentration is purified gained residue with silica gel column chromatography,Obtain: (S)-2-{6-[4-(4-cyclopropyl methyl-piperazine-1-ylmethyl)-phenyl]-thieno [2,3-d] pyrimidine-4-yl amino }-2-phenyl-ethanol (II-3) (42mg, off-white color solid), productive rate: 4.3%.
MSm/z(ESI)：500[M+1]。
1HNMR(400Hz，DMSO-d6)：8.43(m，2H)，8.26(s，1H)，7.75(d，2H)，7.52-7.28(m，7H)，5.48(m，1H)，5.20(t，1H)，3.87(m，1H)，3.68(s，2H)，3.09(m，10H)，1.23(m，1H)，0.68(m，2H)，0.44(m，2H)。
Embodiment 4: preparation Compound I-4 and Compound I I-4
The first step:
Under room temperature, will be dissolved in carrene (27ml, 0.422mol) to carboxyl phenyl boric acid pinacol ester (3g, 12.10mmol)And in DMF (9ml, 0.116mol), add N-hydroxyethyl piperazine (2g, 15.36mmol), and comply withInferior 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (2.79g, 14.4mmol), the N-hydroxy benzo three of addingNitrogen azoles (1.98g, 12.9mmol), triethylamine (2.5ml, 17.99mmol), stirring at room temperature reaction is until TLC monitoring raw materialReact completely, in reactant liquor, add 30ml water, stir 30 minutes, with carrene (100ml*3) extraction, then with fullAnd sodium chloride solution (100ml*2) washing, organic phase anhydrous magnesium sulfate drying, filters, and reduced pressure concentration, obtains: (4-Ethoxy-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (3.0g,White solid), productive rate 68.8%, is used as next step reaction.
Second step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (500mg, 1.43mmol) and(4-ethoxy-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone(1.029g, 2.86mmol) is dissolved in DMF (15ml, 0.194mol), adds successively four triphenylsPhosphine palladium (164mg, 0.143mmol), sodium carbonate liquor (1mol/L, 2.8ml), nitrogen protection, is heated to 80 DEG C until TLCMonitoring raw material reaction is complete, naturally cools to room temperature and adds water (100ml*3) washing, by ethyl acetate (250ml*1) extractionGet, saturated aqueous common salt for organic phase (100ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, decompressionConcentrated, purify gained residue with silica gel column chromatography, obtain: (S)-[4-(2-hydroxyl-ethyl)-piperazine-1-yl]-{ 4-[4-(2-Hydroxyl-1-phenyl-ethamine)-thieno [2,3-d] pyrimidine-6-yl]-phenyl }-ketone (I-4) (300mg, faint yellow solid), producesRate: 41.7%.
MSm/z(ESI)：504[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37-8.27(m，3H)，7.77(d，2H)，7.51-7.22(m，7H)，5.45(m，1H)，5.14(t，1H)，4.46(m，1H)，3.75(m，2H)，3.61(m，2H)，3.49(m，2H)，3.36(m，4H)，2.43(m，4H)。
The 3rd step:
Under room temperature by Lithium Aluminium Hydride (90mg, 2.369mmol) and anhydrous tetrahydro furan (10ml) mix and blend, to reactionOxolane (10ml, the 0.123mol) solution that drips Compound I-4 (250mg, 0.496mmol) in liquid, room temperature is stirredMix reaction 1 hour, be warming up to 50 DEG C of reactions until TLC monitoring raw material reaction is complete, naturally cool to room temperature, to reactant liquorIn add 20ml water, with ethyl acetate (100ml*3) extraction, then use saturated nacl aqueous solution (100ml*2) washing,To organic phase filter with anhydrous magnesium sulfate drying, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-2-(6-{4-[4-(2-hydroxyl-ethyl)-piperazine-1-ylmethyl]-phenyl }-thieno [2,3-d] pyrimidine-4-yl amino }-2-phenyl-ethanol(II-4) (48mg, off-white color solid), productive rate: 4.3%.
MSm/z(ESI)：490[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37-8.29(m，3H)，7.77(d，2H)，7.51-7.22(m，7H)，5.45(m，1H)，5.14(t，1H)，4.46(m，1H)，3.75(m，2H)，3.68(s，2H)，3.61(m，2H)，3.49(m，2H)，3.36(m，4H)，2.43(m，4H)。
Embodiment 5: preparation Compound I-5 and Compound I I-5
The first step:
Under room temperature, will be dissolved in carrene (10ml, 0.156mol) to carboxyl phenyl boric acid pinacol ester (0.894g, 4.8mmol)And in DMF (1ml, 17.78mmol), add N-Boc piperazine (1g, 4.03mmol), and successivelyAdd 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (0.93g, 4.8mmol), N-hydroxy benzo three nitrogenAzoles (0.66g, 4.8mmol), triethylamine (0.84ml, 6.04mmol), stirring at room temperature reaction is until TLC monitoring raw material reactionCompletely, in reactant liquor, add 30ml water, stir 30 minutes, with carrene (100ml*3) extraction, then use saturated chlorineChange sodium solution (100ml*2) washing, organic phase anhydrous magnesium sulfate drying, filters, and reduced pressure concentration, obtains: 4-[4-(4,4,5,5-Tetramethyl-[1,3,2] dioxygen boron 2-yl) benzoyl-]-piperazine-1-tert-butyl ester (1.6g, white solid), productive rate 95.4%.
Second step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (500mg, 1.428mmol) and4-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxygen boron 2-yl) benzoyl-]-piperazine-1-tert-butyl ester (1.189g, 2.857mmol)Be dissolved in DMF (20ml, 0.65mol), add successively tetra-triphenylphosphine palladium (161.8mg, 0.14mmol),Sodium carbonate liquor (1mol/L, 2.5ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally coldBut add 100ml water washing to room temperature, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3)Washing, the organic phase anhydrous magnesium sulfate drying obtaining, filtration, reduced pressure concentration, purifies gained with silica gel column chromatography residualThing, obtains crude product (380mg, faint yellow solid), productive rate: 47.6%. MSm/z (ESI): 560[M+1].
The 3rd step:
Under room temperature, above-mentioned product (168mg, 0.3mmol) is dissolved in carrene (8ml, 0.125mol), addsTrifluoroacetic acid (0.45ml, 0.6mmol), is stirred to TLC monitoring raw material reaction complete under room temperature, reduced pressure concentration, uses saturated carbonAcid hydrogen sodium solution dilution neutralization, with dichloromethane extraction (50ml*3) saturated aqueous common salt for organic layer (50ml*3) washing,Reduced pressure concentration, scrapes large plate, obtains: (S)-and 4-[4-(2-hydroxyl-1-phenyl-ethamine)-thieno (2,3-d) pyrimidine-6-yl]-phenyl }-Piperazine-1-base-ketone (I-5) (50mg, white solid), productive rate: 36%.
MSm/z(ESI)：460[M+1]。
1HNMR(400Hz，DMSO-d6)：8.40(m，1H)，8.24(m，2H)，7.79(d，2H)，7.45(m，4H)，7.21(m，3H)，5.45(m，1H)，5.04(t，1H)，3.55(s，2H)，2.74(m，4H)，2.39(m，4H)。
The 4th step:
Under room temperature by Lithium Aluminium Hydride (51.5mg, 1.355mmol) and anhydrous tetrahydro furan (25,0.308mol) mix and blend,To oxolane (25ml, the 0.308mol) solution that drips Compound I-5 (500mg, 0.451mmol) in reactant liquor,Stirring at room temperature reaction 1 hour, is warming up to 50 DEG C of reactions until TLC monitoring raw material reaction is complete, naturally cools to room temperature, toIn reactant liquor, add 20ml water, with ethyl acetate (50ml*3) extraction, then use saturated nacl aqueous solution (100ml*2) to washWash, the organic phase obtaining is filtered with anhydrous magnesium sulfate drying, and reduced pressure concentration is purified gained residue with silica gel column chromatography,Obtain: (S)-2-phenyl-2-[6-(4-piperazine-1-ylmethyl-phenyl)-thieno [2,3-d] pyrimidine-4-yl amino]-ethanol (II-5)(100mg, white solid), productive rate: 20.7%.
MSm/z(ESI)：446[M+1]。
1HNMR(400Hz，DMSO-d6)：8.41(m，1H)，8.26(m，2H)，7.78(d，2H)，7.46(m，4H)，7.22(m，3H)，5.48(m，1H)，5.06(t，1H)，3.84(m，2H)，3.57(s，2H)，2.76(m，4H)，2.40(m，4H)。
Embodiment 6: preparation Compound I I-6
The first step:
Morpholine (5ml, 57.405mmol) is dissolved in 40ml carrene, under 0 DEG C of ice bath, adds N, N-diisopropylBase ethamine (9.5ml, 57.405mmol), will be dissolved in the triphosgene (6g, 20.69mmol) in carrene (30ml)Slowly drip, drip process temperature and remain on 0 ± 3 DEG C, react 1 hour, under 0 DEG C of ice bath, add N-Boc piperazine(11.8mg, 63.15mmol) and DIPEA (9.5ml, 57.405mmol), stirring reaction under room temperature untilTLC monitoring raw material reaction is complete, and reduced pressure concentration is purified gained residue with silica gel column chromatography, by dissolving crude product in 30mlIn carrene, add stirring reaction under trifluoroacetic acid (14ml, 18.7mmol) room temperature until TLC monitoring raw material reaction is completeEntirely, reduced pressure concentration, adds saturated sodium carbonate solution (50ml*3) washing, with carrene (50ml*6) extraction, decompressionConcentrated, purify gained residue with silica gel column chromatography, obtain: morpholinyl piperazinyl urea (877mg, faint yellow solid),Productive rate: 6%, MSm/z (ESI): 200[M+1].
Second step:
Morpholinyl piperazinyl urea (500mg, 2.51mmol) and 4-formyl phenyl boric acid (396mg, 2.64mmol) are dissolvedIn 20ml oxolane, add acetum (0.5ml, 8.75mmol), stirring at room temperature reaction 1 hour, adds three secondAcyloxy sodium borohydride (798mg, 3.77mmol), is warming up to 60 DEG C of stirring reactions until TLC monitoring raw material reaction is complete,Reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (4-benzyl-piperazine-1-yl)-morpholine-1-base-ketone-boronAcid (330mg, light yellow solid), productive rate: 23%, MSm/z (ESI): 334[M+1].
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (189mg, 0.540mmol) and(4-benzyl-piperazine-1-yl)-morpholine-1-base-ketone-boric acid (150mg, 045mmol) is dissolved in DMF(20ml, 0.65mol), adds tetra-triphenylphosphine palladium (52mg, 0.045mmol) successively, sodium carbonate liquor (1mol/L, 3ml),Nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, and naturally cool to room temperature and add 100ml water washing,With ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtaining is with anhydrousDried over mgso, filters, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-hydroxylBase-1-phenyl-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-morpholine-4-yl)-ketone (II-6)(15mg, white solid), productive rate: 6%.
MSm/z(ESI)：559[M+1]。
1HNMR(400Hz，DMSO-d6)：8.28-8.20(m，3H)，7.69(d，2H)，7.46-7.23(m，7H)，5.45(m，1H)，5.05(t，1H)，3.76(m，2H)，3.55(m，6H)，3.25-3.08(m，8H)，2，39(m，4H)。
Embodiment 7: preparation Compound I I-7
The first step:
Nafoxidine (600mg, 8.436mmol) is dissolved in 15ml carrene, under 0 DEG C of ice bath, adds N, N-Diisopropylethylamine (1.4ml, 8.436mmol), will be dissolved in the triphosgene (801mg, 2.70mmol) in carrene (5ml)Slowly drip, drip process temperature and remain on 0 ± 3 DEG C, react 1 hour, under 0 DEG C of ice bath, add N-Boc piperazine (1.57g,8.436mmol) and DIPEA (1.4ml, 8.436mmol), stirring reaction under room temperature is until TLC monitoring is formerMaterial reacts completely, and dissolving crude product, in 20ml carrene, is added under trifluoroacetic acid (10ml, 0.135mol) room temperature and stirredMix reaction until TLC monitoring raw material reaction is complete, reduced pressure concentration, adds saturated sodium carbonate solution (50ml*3) washing, usesCarrene (50ml*5) extraction, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: nafoxidineBase piperazinyl urea (376mg, faint yellow solid), productive rate: 24%.
MSm/z(ESI)：184[M+1]。
1HNMR(400Hz，DMSO-d6)：3.23(t，5H)，3.05(t，4H)，2.64(t，4H)，1.72(m，4H)。
Second step:
By nafoxidine base piperazinyl urea (370mg, 2.022mmol) and 4-formyl phenyl boric acid (334mg, 2.224mmol)Be dissolved in 10ml oxolane and 10ml methyl alcohol, add acetum (0.5ml, 8.75mmol), stirring at room temperature reaction 1Hour, add sodium triacetoxy borohydride (1.1g, 5.055mmol), be warming up to 60 DEG C of stirring reactions until TLC monitoringRaw material reaction is complete, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (4-benzyl-piperazine-1-yl)-tetra-Hydrogen pyrroles-1-base-ketone-boric acid (210mg), productive rate: 33%.
MSm/z(ESI)：318[M+1]。
1HNMR(400Hz，DMSO-d6)：7.99(s，2H)，7.74(d，2H)，7.25(d，2H)，3.47(s，2H)，3.23(m，4H)，3.16(m，4H)，2.33(m，4H)，1.72(m，4H)。
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (317mg, 0.906mmol) and(4-benzyl-piperazine-1-yl)-nafoxidine-1-base-ketone-boric acid (200mg, 0.604mmol) is dissolved in N, N-dimethyl methylAcid amides (5ml, 65mmol), adds tetra-triphenylphosphine palladium (70mg, 0.0604mmol) successively, sodium carbonate liquor (1mol/L,1ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with carrene (3*100ml) extraction, saturated aqueous common salt for organic phase (100ml*2) washing, what obtain is organicUse mutually anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-hydroxyl-1-phenyl-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-pyrroles-1-base-firstKetone (II-7) (67mg, white solid), productive rate: 20%.
MSm/z(ESI)：543[M+1]。
1HNMR(400Hz，DMSO-d6)：8.28-8.19(m，3H)，7.69(d，2H)，7.46-7.23(m，7H)，5.45(m，1H)，5.05(t，1H)，3.76(m，2H)，3.53(s，2H)，3.25-3.08(m，8H)，2，39(m，4H)，1.74(s，4H)。
Embodiment 8: preparation Compound I I-8
The first step:
Tetramethoxy piperidines (500mg, 4.314mmol) is dissolved in 10ml carrene, under 0 DEG C of ice bath, addsDIPEA (0.72ml, 4.314mmol), will be dissolved in triphosgene in carrene (5ml) (412mg,1.389mmol) slowly drip, drip process temperature and remain on 0 ± 3 DEG C, react 1 hour, under 0 DEG C of ice bath, add N-BocPiperazine (809mg, 4.341mmol) and DIPEA (0.72ml, 4.341mmol), stirring reaction under room temperatureUntil TLC monitoring raw material reaction is complete, reduced pressure concentration, in 20ml carrene, adds trifluoroacetic acid by dissolving crude productStirring reaction under (10ml, 0.135mol) room temperature is until TLC monitoring raw material reaction is complete, and reduced pressure concentration, adds saturated carbonAcid sodium solution (50ml*3) washing, with carrene (50ml*5) extraction, reduced pressure concentration, purifies with silica gel column chromatographyGained residue, obtains: 4-methoxyl group piperidinyl piperazine base urea (414mg, faint yellow solid), and productive rate: 42%, MSm/z (ESI):228[M+1]。
Second step:
By 4-methoxyl group piperidinyl piperazine base urea (414mg, 1.824mmol) and 4-formyl phenyl boric acid (287mg, 1.915mmol)Be dissolved in 5ml oxolane and 5ml methyl alcohol, add acetum (0.2ml, 3.5mmol), it is 1 little that stirring at room temperature is reactedTime, add sodium triacetoxy borohydride (580mg, 2.726mmol), be warming up to 60 DEG C of stirring reactions until TLC monitoringRaw material reaction is complete, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (4-benzyl-piperazine-1-yl)-4-Methoxyl group piperidin-1-yl-ketone-boric acid (251mg, light yellow solid), productive rate: 38.1%, MSm/z (ESI): 362[M+1].
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (181mg, 0.520mmol) and(4-benzyl-piperazine-1-yl)-4-methoxyl group piperidin-1-yl-ketone-boric acid (125mg, 0.346mmol) is dissolved in N, N-diformazanBase formamide (20ml, 0.65mol), adds tetra-triphenylphosphine palladium (40mg, 0.035mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-(4-methoxyl group-piperidin-1-yl)-firstKetone (II-8) (36mg, faint yellow solid), productive rate: 17.7%.
MSm/z(ESI)：587[M+1]。
1HNMR(400Hz，DMSO-d6)：8.31-8.19(m，3H)，7.67(d，2H)，7.46-7.44(m，4H)，7.35-7.22(m，3H)，5.46(m，1H)，5.06(t，1H)，3.77(m，2H)，3.52(s，2H)，3.35(m，7H)，3.20(s，3H)，2.89(m，2H)，2.44(m，4H)，1.81(m，2H)，1.35(m，2H)。
Embodiment 9: preparation Compound I I-9
Under room temperature, Compound I I-5 (100mg, 0.225mmol) is dissolved in DMF (5ml), adds4-bromo crotonic acid (37.2mg, 0.225mmol) and N-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (43.0mg,0.225mmol), stirring at room temperature reaction is until TLC monitoring raw material reaction is complete, reduced pressure concentration, add oxolane (30ml,0.37mol) and dimethylamine (0.5ml, 3.66mmol), stirring at room temperature reaction, until TLC monitoring raw material reaction is complete, adds secondAcetoacetic ester (200ml*1) extraction, organic layer water (50ml*3) is washed, organic phase anhydrous magnesium sulfate drying, suction filtration, subtractsPress concentratedly, purify gained residue with silica gel column chromatography, obtain: (S)-4-dimethylamino-1-(4-{4-[4-(2-hydroxyl-1-benzeneBase-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-butyl-2-alkene-1-ketone (II-9) (40mg, greyish whiteLook solid), productive rate: 32%.
MSm/z(ESI)：557[M+1]。
1HNMR(400Hz，DMSO-d6)：8.36-8.30(m，3H)，7.74(d，2H)，7.53-7.29(m，7H)，6.87(d，1H)，6.64(dd，1H)，5.52(m，1H)，5.12(t，1H)，3.83(m，2H)，3.60(s，2H)，3.58(m，6H)，2.60(s，6H)，2.45(m，4H)。
Embodiment 10: preparation Compound I I-10
The first step:
Piperidines (1g, 11.752mmol) is dissolved in 20ml carrene, under 0 DEG C of ice bath, adds N, N-diisopropylBase ethamine (2ml, 11.752mmol), will be dissolved in the triphosgene (1.1g, 3.761mmol) in carrene (10ml)Slowly drip, drip process temperature and remain on 0 ± 3 DEG C, react 1 hour, under 0 DEG C of ice bath, add N-Boc piperazine (2.2g,11.752mmol) and DIPEA (2ml, 11.752mmol), stirring reaction under room temperature is until TLC monitoring is formerMaterial reacts completely, and reduced pressure concentration in carrene (30ml), adds trifluoroacetic acid (20ml, 0.27mol) by dissolving crude productStirring reaction under room temperature is until TLC monitoring raw material reaction is complete, and reduced pressure concentration, adds saturated sodium carbonate solution (50ml*3)Washing, with carrene (50ml*5) extraction, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains:Piperidinyl piperazine base urea (1.25g, faint yellow solid), productive rate: 36%.
MSm/z(ESI)：198[M+1]。
1HNMR(400Hz，DMSO-d6)：3.59(brs，1H)，3.09(m，8H)，2.78(m，4H)，1.48(m，6H)。
Second step:
Piperidinyl piperazine base urea (1.25g, 6.336mmol) and 4-formyl phenyl boric acid (1.05g, 6.969mmol) are dissolvedIn 15ml oxolane and 15ml methyl alcohol, add acetum (0.7ml, 12.67mmol), stirring at room temperature reaction 1.5Hour, add sodium triacetoxy borohydride (3.36g, 15.84mmol), be warming up to 60 DEG C of stirring reactions until TLC monitoringRaw material reaction is complete, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (4-benzyl-piperazine-1-yl)-piperazinePyridine-1-base-ketone-boric acid (1.25g, light yellow solid), productive rate: 60%.
MSm/z(ESI)：332[M+1]。
1HNMR(400Hz，DMSO-d6)：7.97(s，2H)，7.74(d，2H)，7.25(d，2H)，3.47(s，2H)，3.09(m.8H)，2.33(m，4H)，1.45(m，6H)。
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (317mg, 0.906mmol) and(4-benzyl-piperazine-1-yl)-piperidin-1-yl-ketone-boric acid (200mg, 0.604mmol) is dissolved in DMF(10ml, 0.325mol), adds tetra-triphenylphosphine palladium (70mg, 0.0604mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-piperidin-1-yl)-ketone (II-10)(67mg, off-white color solid), productive rate: 20%.
MSm/z(ESI)：557[M+1]。
1HNMR(400Hz，DMSO-d6)：8.28(m，3H)，7.68(d，2H)，7.44(d，4H)，7.31-7.24(m，3H)，5.45(m，1H)，5.06(t，1H)，3.80(m，2H)，3.54(s，2H)，3.12(m，8H)，2.39(m，4H)，1.19(m，6H)。
Embodiment 11: preparation Compound I I-11
The first step:
NEP (1g, 8.77mmol) is dissolved in 15ml carrene, under 0 DEG C of ice bath, adds N, N-bis-Isopropyl ethamine (1.5ml, 8.77mmol), will be dissolved in the triphosgene (833mg, 2.81mmol) in carrene (10ml)Slowly drip, drip process temperature and remain on 0 ± 3 DEG C, react 1 hour, under 0 DEG C of ice bath, add N-Boc piperazine (1.63g,8.77mmol) and DIPEA (1.5ml, 8.77mmol), stirring reaction under room temperature is until TLC monitoring raw materialReact completely, reduced pressure concentration, in carrene (30ml), adds trifluoroacetic acid (10ml, 0.135mol) by dissolving crude productStirring reaction under room temperature is until TLC monitoring raw material reaction is complete, and reduced pressure concentration, adds saturated sodium carbonate solution (50ml*3)Washing, with carrene (50ml*5) extraction, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains:NEP base piperazine urea (1g, weak yellow liquid), productive rate: 34.97%, MSm/z (ESI): 227[M+1].
Second step:
NEP base piperazine urea (1g, 4.40mmol) and 4-formyl phenyl boric acid (729mg, 4.86mmol) are dissolvedIn 10ml oxolane and 10ml methyl alcohol, add acetum (0.7ml, 12.67mmol), stirring at room temperature reaction 1.5Hour, add sodium triacetoxy borohydride (2.33g, 11mmol), be warming up to 60 DEG C of stirring reactions until TLC monitoring is formerMaterial reacts completely, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (4-benzyl-piperazine-1-yl)-N-secondBase piperazine-1-base-ketone-boric acid (125mg, light yellow solid), productive rate: 8.0%, MSm/z (ESI): 361[M+1].
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[2,3-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (181.8mg, 0.520mmol)(4-benzyl-piperazine-1-yl)-NEP-1-base-ketone-boric acid (125mg, 0.346mmol) is dissolved in N, N-diformazanBase formamide (20ml, 0.65mol), adds tetra-triphenylphosphine palladium (40mg, 0.035mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-N-ethyl-piperazine-1-yl)-ketone(II-11) (120mg, white solid), productive rate: 59%.
MSm/z(ESI)：587[M+1]。
1HNMR(400Hz，DMSO-d6)：8.38(m，2H)，8.27(s，1H)，7.70(d，2H)，7.47(m，4H)，7.26(m，3H)，5.45(m，1H)，5.13(t，1H)，3.80(m，2H)，3.60(s，2H)，3.40-3.05(m，14H)，2.43(m，4H)，1.21(m，3H)。
Embodiment 12: preparation compound III-1 and compound IV-1
The first step:
Wherein the bromo-4-chlorothiophene of 6-[3,2-d] pyrimidine is according to method preparation described in patent WO2009/007421.
Under room temperature by bromo-compound 6-4-chlorothiophene [3,2-d] pyrimidine (2g, 8.01mmol) and L-benzene glycinol (1.65g,12.02mmol) be dissolved in DMF (25ml, 0.32mol), dropping 2.8ml triethylamine (2.03g,20.025mmol), be heated to 60 DEG C until TLC monitoring raw material reaction is complete, naturally cool to room temperature, add 100ml waterWashing, with carrene (3*100ml) extraction, saturated aqueous common salt for organic phase (100ml*2) washing, what obtain is organicUse mutually anhydrous magnesium sulfate drying, filter, reduced pressure concentration, obtains: compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-Phenyl 1-ethanol (1.7g, faint yellow solid), productive rate: 61%.
MSm/z(ESI)：351[M+1]。
1HNMR(400Hz，DMSO-d6)：8.39(s，1H)，8.230(d，1H)，7.60(d，1H)，7.46(m，2H)，7.24(m，3H)，5.48(m，1H)，5.03(t，1H)，3.78(m，2H)。
Second step:
The preparation of wherein (4-ethyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketoneMethod is with the first step of embodiment 1.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (1.2g, 3.43mmol) and (4-Ethyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (2.36g, 6.86mmol)Be dissolved in DMF (36ml, 0.465mol), add successively tetra-triphenylphosphine palladium (0.4g, 0.343mmol),Sodium carbonate liquor (1mol/L, 7ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally coolingAdd 100ml water washing to room temperature, with carrene (3*100ml) extraction, saturated aqueous common salt for organic phase (100ml*2)Washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, and reduced pressure concentration, obtains: (S)-(4-ethyl-piperazine-1-Base)-4-[4-(2-hydroxyl-1-phenyl-ethamine)-thiophene [3,2-d] pyrimidine-6-yl] and-phenyl }-ketone (III-1) (500mg, yellow solid)Productive rate: 30%.
MSm/z(ESI)：487[M+1]。
1HNMR(400Hz，DMSO-d6)：8.42(s，1H)，8.22(d，1H)，7.89(d，2H)，7.85(s，1H)，7.82(m，4H)，7.20-7.46(m，3H)，5.48(m，1H)，5.00(t，1H)，3.83(m，2H)，3.40(m，4H)，2.45(m，4H)，2.27(q，2H)，0.99(t，3H)。
The 3rd step:
Under room temperature, Lithium Aluminium Hydride (75mg, 1.95mmol) and anhydrous tetrahydro furan (5ml, 61.27mmol) mixing are stirredMix, in reactant liquor, drip (4-ethyl-piperazine-1-yl)-{ 4-[4-(2-hydroxyl-1-phenyl-ethylamino)-thieno [3,2, d] pyrimidine-6-yl]-phenyl } oxolane (10ml, the 0.123mol) solution of-ketone (370mg, 0.78mmol), stirring at room temperature is anti-Answer 1 hour, be warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, in 0 DEG C of ice bath downhill reaction liquid, add 20mlWater, with ethyl acetate (50ml*2) extraction, then uses saturated nacl aqueous solution (50ml*3) washing, anhydrous sodium sulfate drying.Decompression steams after solvent with silica gel column chromatography purifies gained residue, obtains: (S)-2-{6-[4-(4-ethyl-piperazine-1-ylmethyl)-Phenyl]-thieno [3,2-d] pyrimidine-4-yl amino }-2-phenyl-ethanol (IV-1) (17mg, faint yellow solid), productive rate: 18.4%.
MSm/z(ESI)：473[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8.19(d，1H)，7.82(d，2H)，7.79(s，1H)，7.82(m，4H)，7.20-7.46(m，3H)，5.47(m，1H)，5.00(t，1H)，3.83(m，2H)，3.52(s，2H)，2.40(brs，8H)，2.27(q，2H)，0.98(t，3H)。
Embodiment 13: preparation compound III-2 and compound IV-2
The first step:
The preparation method of (4-methyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketoneWith the first step of embodiment 2.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (200mg, 0.57mmol) and (4-Methyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (226mg, 0.684mmol)Be dissolved in DMF (10ml, 0.13mol), add successively tetra-triphenylphosphine palladium (66mg, 0.057mmol),Sodium carbonate liquor (1mol/L, 0.5ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally coldBut add 100ml water washing to room temperature, with carrene (3*100ml) extraction, saturated aqueous common salt for organic phase (100ml*2)Washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, and reduced pressure concentration, obtains: (S)-4-[4-(2-hydroxyl-1-phenyl-Ethamine)-thieno [3,2-d] pyrimidine-6-yl]-phenyl }-(4-methyl-piperazine-1-yl)-ketone (III-2) (100mg, yellow solid),Productive rate: 37%.
MSm/z(ESI)：473[M+1]。
1HNMR(400Hz，DMSO-d6)：8.41(s，1H)，8.30(d，1H)，7.87(d，2H)，7.84(s，1H)，7.50(m，4H)，7.27-7.39(m，3H)，5.49(m，1H)，5.10(t，1H)，3.83(s，2H)，3.65-3.60(m，4H)，2.40(m，4H)，2.25(s，3H)。
Second step:
Under room temperature, Lithium Aluminium Hydride (20.14mg, 0.53mmol) and anhydrous tetrahydro furan (5ml, 61.27mmol) are mixedStir, to oxolane (10ml, the 0.123mol) solution that drips compound III-2 in reactant liquor, stirring at room temperature reaction 1Hour, be warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, in 0 DEG C of ice bath downhill reaction liquid, add 20ml water, useEthyl acetate (50ml*2) extraction, then use saturated nacl aqueous solution (50ml*3) washing, anhydrous sodium sulfate drying, decompressionSteam after solvent with silica gel column chromatography and purify gained residue, obtain: (S)-2-{6-[4-(4-methyl-piperazine-1-ylmethyl)-benzeneBase]-thieno [3,2-d] pyrimidine-4-yl amino }-2-phenyl-ethanol (IV-2) (30mg, faint yellow solid), productive rate: 31%.
MSm/z(ESI)：458[M+1]。
1HNMR(400Hz，DMSO-d6)：8.42(s，1H)，8.31(d，1H)，7.87(d，2H)，7.85(s，1H)，7.50(m，4H)，7.27-7.39(m，3H)，5.49(m，1H)，5.10(t，1H)，3.78(m，2H)，3.63(s，2H)，2.84-2.62(m，4H)，2.45(s，3H)，2.52-2.56(m，4H)。
Embodiment 14: preparation compound III-3 and compound IV-3
The first step:
Wherein, (4-cyclopropyl carbonyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-firstThe preparation method of ketone is with the first step of embodiment 3.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (600mg, 1.72mmol) and (4-Cyclopropyl carbonyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (892mg,2.32mmol) be dissolved in DMF (10ml, 0.13mol), add successively tetra-triphenylphosphine palladium (100mg,0.086mmol), sodium carbonate liquor (1mol/L, 2mL), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reactionCompletely, naturally cool to room temperature and add 100ml water washing, with carrene (3*100ml) extraction, the saturated food of organic phaseSalt solution (100ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, and reduced pressure concentration, uses silica gel column chromatographyMethod purifying gained residue, obtains: (S)-(4-cyclopropyl carbonyl-piperazine-1-yl)-{ 4-[4-(2-hydroxyl-1-phenyl-ethamine)-thieno[3,2-d] pyrimidine-6-yl]-phenyl }-ketone (III-3) (862mg, yellow solid), productive rate: 95%.
MSm/z(ESI)：528[M+1]。
1HNMR(400Hz，DMSO-d6)：8.39(s，1H)，8，17(d，1H)，7.84-7.78(m，3H)，7.47-7.43(m，4H)，7.34-7.22(m，3H)，5.46(m，1H)，5.00(t，1H)，3.80-3.76(m，2H)，3.61-3.50(m，8H)，2.0(m，1H)，0.70(m，4H)。
Second step:
Under room temperature, Lithium Aluminium Hydride (54mg, 1.423mmol) and anhydrous tetrahydro furan (10ml, 0.123mol) mixing are stirredMix, to oxolane (10ml, the 0.123mol) solution that drips compound III-3 (300mg, 0.57mmol) in reactant liquor,Stirring at room temperature reaction 1 hour, is warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, 0 DEG C of ice bath downhill reaction liquidIn add 100ml water, with ethyl acetate (100ml*2) extraction, then use saturated nacl aqueous solution (50ml*3) washing, useSilica gel column chromatography purifying gained residue, obtains: (S)-2-{6-[4-(4-cyclopropyl methyl-piperazine-1-ylmethyl)-phenyl]-thiopheneAnd [3,2-d] pyrimidine-4-yl amino }-2-phenyl-ethanol (IV-3) (5mg, white solid), productive rate: 1.76%.
MSm/z(ESI)：499[M+1]。
1HNMR(400Hz，DMSO-d6)：8.39(s，1H)，8，17(d，1H)，7.84-7.78(m，3H)，7.47-7.43(m，4H)，7.34-7.22(m，3H)，5.46(m，1H)，5.00(t，1H)，3.81-3.76(m，2H)，3.55(brs，2H)，2.50(m，10H)，0.90(m，1H)，0.5(m，4H)。
Embodiment 15: preparation compound III-4 and compound IV-4
The first step:
Wherein, (4-ethoxy-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketonePreparation method is with the first step of embodiment 4.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (340mg, 0.97mmol) and (4-Ethoxy-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (454mg,1.26mmol) be dissolved in DMF (10ml, 0.13mol), add successively tetra-triphenylphosphine palladium (112mg,0.097mmol), sodium carbonate liquor (1mol/L, 1ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is completeEntirely, naturally cool to room temperature and add 100ml water washing, with carrene (3*100ml) extraction, organic phase saturated common saltWater (100ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining, filters, and reduced pressure concentration, uses silica gel column chromatographyPurifying gained residue, obtains: (S)-[4-(2-hydroxyl-ethyl)-piperazine-1-yl]-{ 4-[4-(2-hydroxyl-1-phenyl-ethamine)-thieno[3,2-d] pyrimidine-6-yl]-phenyl }-ketone (III-4) (45mg, yellow solid), productive rate: 9.2%.
MSm/z(ESI)：503[M+1]。
1HNMR(400Hz，DMSO-d6)：8.43(s，1H)，8.21(d，1H)，7.92(m，3H)，7.43(m，4H)，7.26(m，3H)，5.49(m，1H)，5.02(t，1H)，3.83(m，4H)，3.56(s，2H)，3.10-3.01(m，6H)，2.78(m，2H)。
Second step:
Under room temperature by Lithium Aluminium Hydride (41.8mg, 11mmol) and anhydrous tetrahydro furan (10ml, 0.123mol) mix and blend,To oxolane (10ml, the 0.123mol) solution that drips compound III-4 (220mg, 0.44mmol) in reactant liquor, chamberTemperature stirring reaction 1 hour, is warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, in 0 DEG C of ice bath downhill reaction liquidAdd 100ml water, with ethyl acetate (100ml*2) extraction, then use saturated nacl aqueous solution (50ml*3) washing, obtainOrganic phase anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains:(S)-2-(6-{4-[4-(2-hydroxyl-ethyl)-piperazine-1-ylmethyl]-phenyl }-thieno [3,2-d] pyrimidine-4-yl amino }-2-phenyl-secondAlcohol (IV-4) (30mg, faint yellow solid), productive rate: 14%.
MSm/z(ESI)：490[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8.20(d，1H)，7.90(m，3H)，7.45(m，4H)，7.25(m，3H)，5.48(m，1H)，5.01(t，1H)，3.85(m，4H)，3.58(s，2H)，3.10(m，8H)，2.80(m，2H)。
Embodiment 16: preparation compound III-5 and compound IV-5
The first step:
Wherein the bromo-4-chlorine of 6-furans [3,2-d] pyrimidine synthetic with reference to bromo-4-chlorothiophene [3, the 2-d] pyrimidine of 6-andPreparation method described in W02008/073785.
Under room temperature by bromo-compound 6-4-chlorine furans [3,2-d] pyrimidine (1g, 4.29mmol) and L-benzene glycinol (0.83g,6.06mmol) be dissolved in DMF (25ml, 0.32mol), drip 1.5ml triethylamine, be heated to60 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature, adds 100ml water washing, uses carrene(3*80ml) extraction, saturated aqueous common salt for organic phase (80ml*2) washing, the organic phase anhydrous magnesium sulfate drying obtaining,Filter, reduced pressure concentration, obtains: 2-(the bromo-furans of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (0.7g, faint yellow solid),Productive rate: 49%, MSm/z (ESI): 335[M+1], be directly used in next step reaction.
Second step:
Under room temperature by compound 2-(the bromo-furans of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (1.2g, 3.59mmol) and (4-Ethyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (2.36g, 6.86mmol)Be dissolved in 36mlN, dinethylformamide, adds tetra-triphenylphosphine palladium (0.41g, 0.359mmol) successively, and sodium carbonate is moltenLiquid (1Mol/L, 7ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and addsEnter 80ml water washing, with carrene (3*80ml) extraction, saturated aqueous common salt for organic phase (80ml*2) washing, obtainsOrganic phase anhydrous magnesium sulfate drying, filter, reduced pressure concentration, obtains: (4-ethyl-piperazine-1-yl)-{ 4-[4-(2-hydroxyl-1-Phenyl-ethylamino) also [3,2, d] pyrimidine-6-yl of-furans]-phenyl }-ketone (III-5) (475mg, yellow solid), productive rate: 28%.
MSm/z(ESI)：472[M+1]。
1HNMR(400Hz，DMSO-d6)：8.40(s，1H)，8.22(d，1H)，7.89(d，2H)，7.48(s，1H)，7.82(m，4H)，7.20-7.46(m，3H)，5.48(m，1H)，5.01(t，1H)，3.83(m，2H)，3.40(m，4H)，2.45(m，4H)，2.27(q，2H)，1.03(t，3H)。
The 3rd step:
Under room temperature by Lithium Aluminium Hydride (75mg, 1.95mmol) and 5mL anhydrous tetrahydro furan mix and blend, in reactant liquorOxolane (10mL, the 0.123mol) solution that drips compound III-5 (355mg, 0.75mmol), stirring at room temperature is anti-Answer 1 hour, be warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, in 0 DEG C of ice bath downhill reaction liquid, add 20mlWater, with ethyl acetate (50ml*2) extraction, then uses saturated nacl aqueous solution (50ml*3) washing, anhydrous sodium sulfate drying.Decompression steams after solvent with silica gel column chromatography purifies gained residue, obtains: (S)-2-{6-[4-(4-ethyl-piperazine-1-ylmethyl)-Phenyl] also [3,2-d] pyrimidine-4-yl amino of-furans }-2-phenyl-ethanol (IV-5) (48mg, faint yellow solid), productive rate: 14%.
MSm/z(ESI)：458[M+1]。
1HNMR(400Hz，DMSO-d6)：8.38(s，1H)，8.20(d，1H)，7.82(d，2H)，7.47(s，1H)，7.82(m，4H)，7.23-7.47(m，3H)，5.46(m，1H)，5.01(t，1H)，3.83(m，2H)，3.52(s，2H)，2.40(brs，8H)，2.28(q，2H)，0.99(t，3H)。
Embodiment 17: preparation compound III-6 and compound IV-6
The first step:
Under room temperature by compound 2-(the bromo-furans of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (198mg, 0.59mmol) and (4-Methyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (226mg, 0.684mmol)Be dissolved in 10mLN, dinethylformamide, adds tetra-triphenylphosphine palladium (66mg, 0.057mmol), sodium carbonate successivelySolution (1mol/L, 0.5ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to chamberTemperature adds 90ml water washing, with carrene (3*80ml) extraction, saturated aqueous common salt for organic phase (80ml*2) washing,The organic phase anhydrous magnesium sulfate drying obtaining, filters, and reduced pressure concentration, obtains: (S)-and 4-[4-(2-hydroxyl-1-phenyl-ethamine)-Furans is [3,2-d] pyrimidine-6-yl also]-phenyl }-(4-methyl-piperazine-1-yl)-ketone (III-6) (95mg, yellow solid) productive rate: 35.8％。
MSm/z(ESI)：458[M+1]。
1HNMR(400Hz，DMSO-d6)：8.43(s，1H)，8.30(d，1H)，7.88(d，2H)，7.48(s，1H)，7.50(m，4H)，7.27-7.41(m，3H)，5.50(m，1H)，5.03(t，1H)，3.83(s，2H)，3.65-3.60(m，4H)，2.40(m，4H)，2.27(s，3H)。
Second step:
Under room temperature, Lithium Aluminium Hydride (20.14mg, 0.53mmol) and anhydrous tetrahydro furan (5ml, 61.27mmol) are mixedStir, molten to the oxolane (10ml, 0.123mol) that drips compound III-6 (90mg, 0.19mmol) in reactant liquorLiquid, stirring at room temperature reaction 1 hour, is warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, under 0 DEG C of ice bath to insteadAnswer in liquid and add 20ml water, with ethyl acetate (40ml*2) extraction, then use saturated nacl aqueous solution (40ml*3) washing,Anhydrous sodium sulfate drying. Decompression steams after solvent with silica gel column chromatography purifies gained residue, obtains: (S)-2-{6-[4-(4-Methyl-piperazine-1-ylmethyl)-phenyl] also [3,2-d] pyrimidine-4-yl amino of-furans }-2-phenyl-ethanol (IV-6) (25mg, faint yellowSolid), productive rate: 28.7%.
MSm/z(ESI)：444[M+1]。
1HNMR(400Hz，DMSO-d6)：8.43(s，1H)，8.32(d，1H)，7.87(d，2H)，7.49(s，1H)，7.50(m，4H)，7.27-7.39(m，3H)，5.49(m，1H)，5.11(t，1H)，3.78(m，2H)，3.63(s，2H)，2.84-2.62(m，4H)，2.47(s，3H)，2.52-2.56(m，4H)。
Embodiment 18: preparation compound III-7 and compound IV-7
The first step:
Under room temperature by compound 2-(the bromo-furans of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (290mg, 0.868mmol) and(4-cyclopropyl carbonyl-piperazine-1-yl)-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxy boron, penta encircle-2-yl)-phenyl]-ketone (445mg,1.16mmol) be dissolved in 5mLN, in dinethylformamide, add successively tetra-triphenylphosphine palladium (50mg, 0.043mmol),Sodium carbonate liquor (1mol/L, 2mL), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally coldBut add 80mL water washing to room temperature, with carrene (3*80mL) extraction, saturated aqueous common salt for organic phase (80ml*2)Washing, the organic phase anhydrous magnesium sulfate drying obtaining, filtration, reduced pressure concentration, purifies gained with silica gel column chromatography residualThing, obtains: (S)-(4-cyclopropyl carbonyl-piperazine-1-yl)-also [3,2-d] pyrimidine-6-yl of 4-[4-(2-hydroxyl-1-phenyl-ethamine)-furans]-Phenyl }-ketone (III-7) (350mg, yellow solid), productive rate: 79%.
MSm/z(ESI)：512[M+1]。
1HNMR(400Hz，DMSO-d6)：8.41(s，1H)，8.19(d，1H)，7.86-7.75(m，3H)，7.49-7.40(m，4H)， 7.36-7.22(m，3H)，5.48(m，1H)，5.01(t，1H)，3.80-3.78(m，2H)，3.67-3.52(m，8H)，2.01(m，1H)，0.70(m，4H)。
Second step:
Under room temperature by Lithium Aluminium Hydride (60mg, 1.578mmol) and 10mL anhydrous tetrahydro furan mix and blend, to reactant liquorThe 10mL tetrahydrofuran solution of middle dropping compound III-7 (290mg, 0.567mmol), stirring at room temperature reaction 1 hour,Be warming up to 55 DEG C of reactions until TLC monitoring raw material reaction is complete, in 0 DEG C of ice bath downhill reaction liquid, add 80ml water, use acetic acidEthyl ester (90ml*2) extraction, then use saturated nacl aqueous solution (60ml*3) washing, purifies gained with silica gel column chromatography residualStay thing, obtain: (S)-2-{6-[4-(4-encircles the third methyl-piperazine-1-methyl)-phenyl] also [3,2-d] pyrimidine-4-amino of-furans }-2-phenyl-Ethanol (IV-7) (75mg, white solid), productive rate: 27.4%.
MSm/z(ESI)：484[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8.17(d，1H)，7.83-7.78(m，3H)，7.47-7.43(m，4H)，7.34-7.19(m，3H)，5.45(m，1H)，5.02(t，1H)，3.81-3.76(m，2H)，3.56(brs，2H)，2.59(m，10H)，2.02(m，1H)，0.68(m，4H)。
Embodiment 19: preparation compound III-8
The first step:
Under room temperature, will be dissolved in carrene (27ml, 0.422mol) to carboxyl phenyl boric acid pinacol ester (2.8g, 11.3mmol)And in DMF (9ml, 0.116mol), add 1-Boc-3-methyl piperazine (2.9g, 14.52mmol),Add successively 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (2.79g, 14.55mmol), N-hydroxy benzoTriazole (1.98g, 14.66mmol), triethylamine (2.5ml, 17.99mmol), stirring at room temperature reaction is until TLC monitoringRaw material reaction is complete, in reactant liquor, adds 30ml water, stir 30 minutes, and with carrene (100ml*3) extraction, thenWith saturated nacl aqueous solution (100ml*2) washing, organic phase anhydrous magnesium sulfate drying, filters, and reduced pressure concentration, obtains:Phenyl boric acid pinacol ester (4.1g, white solid), productive rate 85.4%.
MSm/z(ESI)：431[M+1]。
1HNMR(400Hz，DMSO-d6)：7.79(d，2H)，7.43(d，2H)，3.79(m，3H)，3.36(m，4H)，1.52(s，9H)，1.40(s，12H)，1.18(d，3H)。
Second step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (700mg, 2.0mmol) and upperThe phenyl boric acid pinacol ester (1290mg, 3.0mmol) of one step gained be dissolved in DMF (10ml,0.129mol), add successively tetra-triphenylphosphine palladium (115mg, 0.1mmol), sodium carbonate liquor (1mol/L, 2ml), nitrogenProtection, is heated to 80 DEG C until TLC monitoring raw material reaction is complete, and naturally cool to room temperature and add water (100ml*3) washing,With ethyl acetate (250ml*1) extraction, saturated aqueous common salt for organic phase (100ml*2) washing, the organic phase nothing obtainingWater magnesium sulfate is dry, filters, and reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-4-(4-(4-(2-Hydroxyl-1-phenyl ethylamine)-thiophene [3,2-d] pyrimidine-6-yl) benzoyl)-3-methyl piperazine-1-carboxylic acid tert-butyl ester (III-8) (900mg, lightYellow solid), productive rate: 78%.
MSm/z(ESI)：574[M+1]。
1HNMR(400Hz，DMSO-d6)：8.39(s，1H)，8.24(d，1H)，7.92(m，3H)，7.54(d，2H)，7.45(d，2H)，7.25(m，3H)，5.46(m，1H)，4.99(t，1H)，3.82(m，2H)，3.20-2.90(m，7H)，1.42(s，9H)，1.16(d，3H)。
Embodiment 20: preparation compound III-9
Under room temperature by (S)-4-(4-(4-(2-hydroxyl-1-phenyl ethylamine)-thiophene [3,2-d] pyrimidine-6-yl) benzoyl)-3-methyl piperazine-1-Carboxylic acid tert-butyl ester (III-8) (900mg, 1.57mmol) is dissolved in carrene (10ml, 0.156mol), adds trifluoroAcetic acid (2.4ml, 31.4mmol), is stirred to TLC monitoring raw material reaction complete under room temperature, reduced pressure concentration, uses unsaturated carbonateHydrogen sodium solution dilution neutralization, with dichloromethane extraction (50ml*3) saturated aqueous common salt for organic layer (50ml*3) washing, subtractsPress and concentrate, scrape large plate, obtain: (S)-(4-(4-(2-hydroxyl-1-phenyl ethylamine)-thiophene [3,2-d] pyrimidine-6-yl) phenyl) (2-methyl piperazinePiperazine-1-yl) ketone (III-9) (550mg, white solid), productive rate: 74%.
MSm/z(ESI)：474[M+1]。
1HNMR(400Hz，DMSO-d6)：8.44(s，1H)，8.32(d，1H)，8.00(m，3H)，7.65(d，2H)，7.49(d，2H)，7.34(m，3H)，5.51(m，1H)，5.06(t，1H)，3.84(m，2H)，3.44-3.08(m，7H)，1.41(d，3H)。
Embodiment 21: prepare chemical combination materialization IV-8
Under room temperature, Lithium Aluminium Hydride (132mg, 3.479mmol) and anhydrous tetrahydro furan (30ml, 0.369mol) mixing are stirredMix, in reactant liquor, drip (S)-(4-(4-(2-hydroxyl-1-phenyl ethylamine)-thiophene [3,2-d] pyrimidine-6-yl) phenyl) (2-methyl piperazine-1-Base) oxolane (30ml, the 0.369mol) solution of ketone (III-9) (550mg, 116mmol), stirring at room temperature reaction 1Hour, be warming up to 50 DEG C of reactions until TLC monitoring raw material reaction is complete, naturally cool to room temperature, in reactant liquor, add 20mlWater, with ethyl acetate (100ml*3) extraction, then uses saturated nacl aqueous solution (100ml*2) washing, the organic phase obtainingFilter with anhydrous magnesium sulfate drying, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-2-{6-[4-(2-Methyl-piperazine-1-methyl)-phenyl]-thiophene [3,2-d] pyrimidine-4-amino }-2-phenyl-ethanol (IV-8) (142mg, off-white color solid),Productive rate: 26.7%.
MSm/z(ESI)：460[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8.34(d，1H)，7.83(m，3H)，7.47(m，4H)，7.25(m，3H)，5.44(m，1H)，5.14(t，1H)，3.78(m，2H)，3.56(brs，2H)，3.44-3.08(m，7H)，1.32(d，3H)。
Embodiment 22: prepare chemical combination materialization IV-9
Wherein, the preparation method of (4-benzyl-piperazine-1-yl)-nafoxidine-1-base-ketone-boric acid is with described in embodiment 7.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (174mg, 0.497mmol) and(4-benzyl-piperazine-1-yl)-nafoxidine-1-base-ketone-boric acid (105mg, 0.331mmol) is dissolved in N, N-dimethyl methylAcid amides (5ml, 65mmol), adds tetra-triphenylphosphine palladium (38mg, 0.033mmol) successively, sodium carbonate liquor (1mol/L,1ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with carrene (3*100ml) extraction, saturated aqueous common salt for organic phase (100ml*2) washing, what obtain is organicUse mutually anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains:(S)-(4-{4-[4-(2-hydroxyl-1-phenyl-ethylamino)-thieno [3,2-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-pyrroles-1-base-Ketone (IV-9) (7mg, white solid), productive rate: 3.9%.
MSm/z(ESI)：543[M+1]。
1HNMR(400Hz，DMSO-d6)：8.36(s，1H)，8.15(d，1H)，7.83-7.77(m，3H)，7.47-7.42(m，4H)，7.24-7.21(m，3H)，5.44(m，1H)，4.97(t，1H)，3.75(m，2H)，3.54(s，2H)，3.25-3.17(m，8H)，2.40-2.38(m，4H)，1.75(m，4H)。
Embodiment 23: prepare chemical combination materialization IV-10
Wherein, the preparation method of (4-benzyl-piperazine-1-yl)-4-methoxyl group piperidin-1-yl-ketone-boric acid is with described in embodiment 8.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (181mg, 0.520mmol) and(4-benzyl-piperazine-1-yl)-4-methoxyl group piperidin-1-yl-ketone-boric acid (125mg, 0.346mmol) is dissolved in N, N-diformazanBase formamide (20ml, 0.65mol), adds tetra-triphenylphosphine palladium (40mg, 0.035mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [3,2-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-(4-methoxyl group-piperidin-1-yl)-firstKetone (IV-10) (28mg, white solid), productive rate: 13.8%.
MSm/z(ESI)：587[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8，18(d，1H)，7.84-7.79(m，3H)，7.47-7.44(m，4H)，7.32-7.22(m，3H)，5.45(m，1H)，4.99(t，1H)，3.81-3.72(m，2H)，3.52(s，2H)，3.37(s，1H)，3.35(s，3H)，3.14(m，4H)，2.90(m，2H)，2.40(m，4H)，1.80(m，2H)，1.36(m，4H)。
Embodiment 24: prepare chemical combination materialization IV-11
Wherein, the preparation method of (4-benzyl-piperazine-1-yl)-morpholine-1-base-ketone-boric acid is with described in embodiment 6.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (189mg, 0.540mmol) and(4-benzyl-piperazine-1-yl)-morpholine-1-base-ketone-boric acid (150mg, 045mmol) is dissolved in DMF(20ml, 0.65mol), adds tetra-triphenylphosphine palladium (52mg, 0.045mmol) successively, sodium carbonate liquor (1mol/L, 3ml),Nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, and naturally cool to room temperature and add 100ml water washing,With ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtaining is with anhydrousDried over mgso, filters, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-hydroxylBase-1-phenyl-ethylamino)-thieno [3,2-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-morpholine-4-yl)-ketone (IV-11)(25mg, white solid), productive rate: 14%.
MSm/z(ESI)：559[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8.21(d，1H)，7.84-7.79(m，3H)，7.45-7.41(m，4H)，7.29-7.22(m，3H)，5.42(m，1H)，5.00(t，1H)，3.78(m，2H)，3.53(m.6H)，3.20-3.10(m，8H)，2.41-2.39(m，4H)。
Embodiment 25: prepare chemical combination materialization IV-12
Wherein the preparation method of (4-benzyl-piperazine-1-yl)-piperidin-1-yl-ketone-boric acid is with described in embodiment 10.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (317mg, 0.906mmol) and(4-benzyl-piperazine-1-yl)-piperidin-1-yl-ketone-boric acid (200mg, 0.604mmol) is dissolved in DMF(10ml, 0.325mol), adds tetra-triphenylphosphine palladium (70mg, 0.0604mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [3,2-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-piperidin-1-yl)-ketone (IV-12)(25mg, off-white color solid), productive rate: 7.5%.
MSm/z(ESI)：557[M+1]。
1HNMR(400Hz，DMSO-d6)：8.37(s，1H)，8.16(d，1H)，7.84-7.78(m，3H)，7.47-7.22(m，7H)，5.45(m，1H)，4.97(t，1H)，3.7(m，2H)，3.55(s，2H)，3.11(m，8H)，2.39(m，4H)，1.49(m，6H)。
Embodiment 26: prepare chemical combination materialization IV-13
Wherein (4-benzyl-piperazine-1-yl)-NEP-1-base-ketone-boric acid preparation method is with described in embodiment 11.
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (181.8mg, 0.520mmol)(4-benzyl-piperazine-1-yl)-NEP-1-base-ketone-boric acid (125mg, 0.346mmol) is dissolved in N, N-diformazanBase formamide (20ml, 0.65mol), adds tetra-triphenylphosphine palladium (40mg, 0.035mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [3,2-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-N-ethyl-piperazine-1-yl)-ketone(IV-13) (110mg, white solid), productive rate: 54%.
MSm/z(ESI)：587[M+1]。
1HNMR(400Hz，DMSO-d6)：8.38(s，1H)，8.22(m，1H)，7.85(m，3H)，7.50(m，4H)，7.31(m，3H)， 5.47(m，1H)，5.00(m，1H)，3.78(m，2H)，3.59(s，2H)，3.40-2.95(m，14H)，2.43(m，4H)，1.25(m，3H)。
Embodiment 27: prepare chemical combination materialization IV-14
The first step:
N methyl piperazine (1.5g, 10mmol) is dissolved in 15ml carrene, under 0 DEG C of ice bath, adds N, N-bis-Isopropyl ethamine (1.65ml, 10mmol), will be dissolved in the triphosgene (950mg, 3.2mmol) in carrene (10ml)Slowly drip, drip process temperature and remain on 0 ± 3 DEG C, react 1 hour, under 0 DEG C of ice bath, add N-Boc piperazine (1.9g,10mmol) and DIPEA (1.65ml, 10mmol), stirring reaction under room temperature is until TLC monitoring raw material is anti-Should be complete, reduced pressure concentration, in carrene (30ml), adds trifluoroacetic acid (10ml, 0.135mol) by dissolving crude productStirring reaction under room temperature is until TLC monitoring raw material reaction is complete, and reduced pressure concentration, adds saturated sodium carbonate solution (50ml*3)Washing, with carrene (50ml*5) extraction, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains:N methyl piperazine base piperazine urea (2.3g, weak yellow liquid), productive rate: 50%.
MSm/z(ESI)：213[M+1]。
Second step:
By molten to N methyl piperazine base piperazine urea (2.3g, 10.85mmol) and 4-formyl phenyl boric acid (1.9g, 11.93mmol)Solution, in 20ml oxolane and 10ml methyl alcohol, adds acetum (1.2ml, 21.72mmol), stirring at room temperature reaction 1.5Hour, add sodium triacetoxy borohydride (5.8g, 27.12mmol), be warming up to 60 DEG C of stirring reactions until TLC monitoringRaw material reaction is complete, and reduced pressure concentration is purified gained residue with silica gel column chromatography, obtains: (4-benzyl-piperazine-1-yl)-N-Methylpiperazine-1-yl-ketone-boric acid (1.1g, white solid), productive rate: 50%, MSm/z (ESI): 347[M+1].
The 3rd step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (195mg, 0.75mmol) and (4-Benzyl-piperazine-1-yl)-N methyl piperazine-1-base-ketone-boric acid (174mg, 0.5mmol) is dissolved in N, N-dimethyl formylAmine (20ml, 0.65mol), adds tetra-triphenylphosphine palladium (58mg, 0.05mmol) successively, sodium carbonate liquor (1mol/L,3ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-(4-{4-[4-(2-Hydroxyl-1-phenyl-ethylamino)-thieno [2,3-d] pyrimidine-6-yl]-benzyl }-piperazine-1-yl)-N-methyl-piperazine-1-yl)-ketone(IV-14) (28mg, white solid), productive rate: 10%.
MSm/z(ESI)：572[M+1]。
1HNMR(400Hz，DMSO-d6)：8.38(s，1H)，8.30(d，1H)，7.80(m，3H)，7.44(m，4H)，7.24(m，3H)，5.45(m，1H)，5.10(m，1H)，3.78(m，2H)，3.60(s，2H)，3.52-3.18(m，12H)，2.42(m，4H)，2.38(s，3H)。
Embodiment 28: prepare chemical combination materialization IV-15
The first step:
N-Boc piperazine (5g, 26.8mmol) and 4-formyl phenyl boric acid (2.68g, 17.9mmol) are dissolved in to 15ml tetra-In hydrogen furans and 15ml methyl alcohol, add acetum (6ml, 43.44mmol), stirring at room temperature reaction 1.5 hours, adds threeAcetoxyl group sodium borohydride (9.49g, 44.7mmol), is warming up to 60 DEG C of stirring reactions until TLC monitoring raw material reaction is complete,Reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: 4-benzyl-piperazine-1-carboxylic acid tert-butyl ester-boric acid 4.98g,White solid), productive rate: 87.4%, MSm/z (ESI): 321[M+1], be directly used in next step reaction.
Second step:
Under room temperature by compound 2-(the bromo-thiophene of 6-[3,2-d] pyrimidine-4-yl amine)-2-phenyl 1-ethanol (1g, 2.856mmol) and 4-Benzyl-piperazine-1-carboxylic acid tert-butyl ester-boric acid (1.83g, 5.714mmol) be dissolved in DMF (30ml,0.975mol), add successively tetra-triphenylphosphine palladium (323mg, 0.28mmol), sodium carbonate liquor (1mol/L, 5ml), nitrogenProtection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml water washing, uses secondAcetoacetic ester (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase anhydrous slufuric acid obtainingMagnesium is dry, filters, and reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: 4-(4-{4-[4-(2-hydroxyl-1-Phenyl-ethylamino-thieno [3,2-d]-benzyl }-piperazine-1-carbonyl-piperazine-1-carboxylic acid tert-butyl ester (1.1g, white solid), producesRate: 70.6%, MSm/z (ESI): 546[M+1].
The 3rd step:
By 4-(4-{4-[4-(and 2-hydroxyl-1-phenyl-ethylamino-thieno [3,2-d]-benzyl }-piperazine-1-carbonyl-piperazine-1-carboxylic acidThe tert-butyl ester (1.09g, 2mmol) is dissolved in oxolane, adds trifluoroacetic acid (3ml, 40mmol), stirring at room temperature 2Hour, by the extraction of 400ml ethyl acetate, saturated common salt water washing (100ml*2), the organic phase nothing obtaining for organic phaseWater magnesium sulfate is dry, filters, and reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-2-phenyl-2-[6-(4-Piperazine-1-ylmethyl-phenyl)-thieno [3,2-d] pyrimidine-4-yl amino]-ethanol (IV-15) (700mg, faint yellow solid), producesRate: 78.6%.
MSm/z(ESI)：446[M+1]。
1HNMR(400Hz，DMSO-d6)：8.39(s，1H)，8.18(d，1H)，7.80(m，3H)，7.43(m，4H)，7.27(m，2H)，7.22(m，1H)，5.45(m，1H)，5.00(m，1H)，3.83(m，2H)，3.51(s，2H)，2.71(m，4H)，2.27(m，4H)。
Embodiment 29: prepare chemical combination materialization IV-16
The first step:
Under room temperature by 1-cyclopropane carbonyl piperazine (2.37g, 15.37mmol) with to formyl phenyl boric acid (1.92g, 12.81mmol)Be dissolved in (40ml) in carrene, stirring at room temperature 1 hour, then add inwards sodium cyanoborohydride (1.77g, 28.18mmol),Stirring at room temperature reacts completely to TLC monitoring, and the 20ml that adds water with dichloromethane extraction, then uses saturated common salt water washing 2 times,Organic phase anhydrous magnesium sulfate drying, reduced pressure concentration, obtains: (4-benzyl boric acid-piperazine-1-yl)-cyclopropyl-ketone, (1.6g,White solid), productive rate: 43.4%, be directly used in next step reaction.
Second step:
Wherein the bromo-4-chloro-2-methyl-thiophene of 6-[3,2-d] pyrimidine can referenced patent WO2009/007421 andMethod preparation described in WO2008/058285.
Under room temperature by bromo-6-4-chloro-2-methyl-thiophene [3,2-d] pyrimidine (830mg, 3.15mmol) and L-benzene glycinol (648mg,4.725mmol) be dissolved in (10ml) in DMF, drip triethylamine (1.1ml, 7.875mol), heatingTo 55 DEG C, react 24 hours, naturally cooling, add 40ml frozen water, decompress filter, decompression after the making beating of 10ml water for filter cakeSuction filtration, then pull an oar with 10ml n-hexane, decompress filter, obtains: 2-(the bromo-2-methyl-thiophene of 6-[3,2-d] pyrimidine-4-amino)-2-Phenyl-ethanol (780mg, faint yellow solid), productive rate: 71%.
MSm/z(ESI)：365[M+1]。
1HNMR(400Hz，DMSO-d6)：8.12(d，1H)，7.46(m，3H)，7.29-7.19(m，3H)，5.45(m，1H)，4.98(t，1H)，3，75(m，2H)，2.38(s，3H)。
The 3rd step:
Under room temperature by compound 2-(the bromo-2-methyl-thiophene of 6-[3,2-d] pyrimidine-4-amino)-2-phenyl-ethanol (364mg,1.0mmol) be dissolved in N, N-dimethyl with (4-benzyl boric acid-piperazine-1-yl)-cyclopropyl-ketone (576mg, 2.0mmol)Formamide (10ml, 0.325mol), adds tetra-triphenylphosphine palladium (70mg, 0.0604mmol) successively, sodium carbonate liquor (1mol/L,2ml), nitrogen protection, is heated to 85 DEG C until TLC monitoring raw material reaction is complete, naturally cools to room temperature and adds 100ml waterWashing, with ethyl acetate (100ml*2) extraction, saturated aqueous common salt for organic phase (50ml*3) washing, the organic phase obtainingWith anhydrous magnesium sulfate drying, filter, reduced pressure concentration, purifies gained residue with silica gel column chromatography, obtains: (S)-cyclopropyl-(4-{4-[4-(2-hydroxyl-1-phenyl-ethamine)-2-methyl-thiophene [3,2-d] pyrimidine-6-yl]-phenyl }-piperazine-1-yl)-ketone (IV-16)(110mg, white solid), productive rate: 21%.
MSm/z(ESI)：528[M+1]。
1HNMR(400Hz，DMSO-d6)：8.05(d，1H)，7.81(d，2H)，7.70(s，1H)，7.46(m，5H)，7.31-7.21(m，3H)，5.52(m，1H)，4.99(m，1H)，3.80(m，2H)，3.68(s，2H)，3.56(m，4H)，2.52(s，3H)，2.41(m，4H)，1.96(m，1H)，0.73(m，4H)。
Biological assessment
1. receptor tyrosine kinase EGFR, VEGFR molecular level enzyme are lived and are suppressed preliminary assessment
(1) 4: 1 use of enzyme reaction substrate Poly (Glu, Tyr) is without PBS (10mM sodium phosphate buffer, the 150mmol/L of potassium ionNaCl, pH=7.2～7.4) be diluted to 20 μ g/ml, 125 μ l/ hole coated elisa plates, put 37 DEG C of reactions 12～16 hours, discard holeMiddle liquid, washes plate, washes plate three times with the T-PBS in 200 μ l/ holes (containing the PBS without potassium ion of 0.1%Tween-20), each5 minutes; Dry ELISA Plate 1～2 hour in 37 DEG C of baking ovens.
(2) every hole adds with reaction buffer (50mmol/LHEPESpH7.4,50mmol/LMgCl2，0.5mmol/LMnCl2，0.2mmol/LNa3VO4, 1mmol/LDTT) dilution ATP solution 50 μ L, final concentration 5 μ mol/L. Every holeIn add the compound solution (1%DMSO dissolve, final concentration is 10 μ mol/L) of 1 μ l, then add 50 μ l reaction bufferingThe c-Met tyrosine-kinase zymoprotein of liquid dilution; Put 37 DEG C of shaking tables (100rpm) reaction 1 hour; Each experiment is established without ATP coupleAccording to two holes, hole and corresponding DMSO solvent control hole (negative control hole); Discard liquid in hole, T-PBS washes plate three times.
(3) add antibody PY99100 μ l/ hole (the T-PBS dilution containing BSA5mg/ml for antibody, concentration is 0.4 μ g/ml),37 DEG C of shaking tables react 0.5 hour; Discard liquid in hole, T-PBS washes plate three times.
(4) add the sheep anti mouse two of horseradish peroxidase-labeled to resist the 100 μ l/ holes (T-PBS containing BSA5mg/ml for antibodyDilution, concentration is 0.5 μ g/ml), 37 DEG C of shaking tables react 0.5 hour, discard liquid in hole, and T-PBS washes plate three times.
(5) add the OPD nitrite ion 100 μ l/ holes of 2mg/ml (with containing 0.03%H2O20.1M citric acid-citric acidSodium buffer solution (pH=5.4) dilution), 25 DEG C of lucifuges are reacted 1～10 minute; (need be with ultrasonic when OPD dissolves, nitrite ion need now be joinedNow use).
(6) add 2mol/LH2SO450 μ l/ hole stopped reactions, read with the wavelengthtunable orifice plate ELIASA VERSAmax that declinesNumber, wavelength is 490nm.
(7) inhibiting rate of sample is tried to achieve by following formula:
Test result is shown in Table 1.
2, receptor tyrosine kinase EGFR, VEGFR enzyme are lived and are suppressed IC50Evaluation experimental
Clearly have EGFR or VEGFR enzyme that above-mentioned screening is obtained live that (compound is 10 for inhibiting compound-5MTo the inhibiting rate > 50% of receptor tyrosine kinase EGFR or VEGFR) be made into gradient concentration, carry out IC50Evaluate. With fourParametric method is calculated the IC of the horizontal CKIs EGFR-TK of each compound molecule50Value, the results are shown in Table shown in 1.
Table 1 embodiment compound is lived and is suppressed experimental result the enzyme of EGFR-TK EGFR and VEGFR
From table 1: in Thienopyrimidine of the present invention and furans miazines derivative, majority of compounds is to epidermisIt is active that growth factor receptors EGFR has obvious inhibition, and part of compounds has good to angiogenesis factor acceptor VEGFRGood inhibitory action, also has part of compounds and to EGF Receptor EGFR and angiogenesis factor acceptor VEGFRAll there is good inhibitory action; And there is the also compound activity of [3,2-d] pyrimidine skeleton and be obviously better than having also [2,3-d] pyrimidineThe compound activity of skeleton; The active order of quality of substituting group on piperazine ring roughly can be arranged as: cyclopropyl > methyl > 2-Ethoxy > ethyl > urea; There is the also EGFR of the majority of compounds of [3,2-d] pyrimidine skeleton and suppress activity and control drugGefitinib Gefitinib quite or better, especially compound III-9 and IV-3, its half-inhibition concentration IC50Value is respectively193nM and 118nM, better than positive control medicine Gefitinib, be worth further exploitation; Compound III-2, III-3, III-8, IV-1, IV-2, IV-3, IV-11 also has obvious VEGFR and suppresses active, its half-inhibition concentration IC50Lower than 1Micromole, has prospect in medicine.
Claims (11)
1. Thienopyrimidine and a furans miazines derivative, is characterized in that, is to have general formula I I:
Compound, in general formula: Ar1、Ar2Be phenyl, X is sulphur, and Z is nitrogen, R be hydrogen,Containing the alkyl of 1～6 carbon atom, containing any one in alkene acyl group, the amide groups of 2～6 carbon atoms; Or,To there is general formula IV:
Compound, in general formula: Ar1、Ar2Be phenyl, X is oxygen or sulphur, and Z is nitrogen, and R isHydrogen, containing the alkyl of 1～6 carbon atom, containing any one in cycloalkyl acyl group, the amide groups of 3～6 carbon atoms.
2. the Thienopyrimidine that the general formula I I described in a claim 1 represents and the preparation side of furans miazines derivativeMethod, is characterized in that, comprise the steps 5. or step 2. and 5. step 4. and 5. or step 2. and 4. and 5.:
3. the Thienopyrimidine that the general formula IV described in a claim 1 represents and the preparation side of furans miazines derivativeMethod, is characterized in that, comprise the steps 8. or step 4. and 8. step 6. and 8. or step 4. and 6. and 8.:
4. an application rights requires the Thienopyrimidine described in 1 and furans miazines derivative or described derivativeAny one in dynamic isomer, racemic modification, enantiomter, diastereoisomer, pharmaceutically acceptable salt orTyrosine kinase inhibitor prepared by several mixtures.
5. tyrosine kinase inhibitor claimed in claim 4 refers to EGFR and/or VEGFR inhibitor.
6. EGFR claimed in claim 5 and/or VEGFR inhibitor are at preparation prevention or treatment and epidermal growth factor receptorApplication in the medicine of body EGFR and/or Angiogenesis factor receptors VEGFR relevant disease.
7. EGFR claimed in claim 5 and/or VEGFR inhibitor are at preparation prevention or treatment and epidermal growth factor receptorAbnormal cell proliferation that body EGFR and/or Angiogenesis factor receptors VEGFR are relevant, metamorphosis, hypoerkinesia,Application in the medicine of angiogenesis and metastases disease.
8. EGFR claimed in claim 5 and/or VEGFR inhibitor are at preparation prevention or treatment and epidermal growth factor receptorApplication in the medicine of the growth and metastasis of tumours that body EGFR and/or Angiogenesis factor receptors VEGFR are relevant.
9. the dynamic isomer with following compound or described compound, racemic modification, enantiomter, non-mapping are differentThe mixture of any one or a few in structure body, pharmaceutically acceptable salt be active fraction preparation EGFR and/orVEGFR inhibitor:
10. the pharmaceutically acceptable salt described in claim 4 or 9, refer in inorganic acid salt or acylate arbitrarilyOne or more.
Pharmaceutically acceptable salt described in 11. claims 4 or 9, refer to hydrochloride, hydrobromate, nitrate,Sulfate, phosphate, formates, acetate, propionate, benzoate, maleate, fumarate, succinate,Any one in tartrate, citrate, metilsulfate, ethyl sulfonate, benzene sulfonate, tosilateOr several.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110342682.0A CN103087077B (en) | 2011-11-03 | 2011-11-03 | Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically |
| PCT/CN2012/083830 WO2013064068A1 (en) | 2011-11-03 | 2012-10-31 | Thienopyrimidine and furopyrimidine derivatives, preparation method thereof and medical use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110342682.0A CN103087077B (en) | 2011-11-03 | 2011-11-03 | Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103087077A CN103087077A (en) | 2013-05-08 |
| CN103087077B true CN103087077B (en) | 2016-05-18 |
Family
ID=48191336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110342682.0A Active CN103087077B (en) | 2011-11-03 | 2011-11-03 | Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103087077B (en) |
| WO (1) | WO2013064068A1 (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2738493T3 (en) | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | JAK2 and ALK2 inhibitors and methods for their use |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| CN105418632B (en) * | 2014-09-19 | 2020-02-21 | 上海创诺医药集团有限公司 | Thienopyrimidine derivative, preparation method and medical application thereof |
| WO2016041201A1 (en) * | 2014-09-19 | 2016-03-24 | 上海创诺医药集团有限公司 | Thienopyrimidine derivatives and preparation method therefor and medical application thereof |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2016049524A1 (en) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| CN105524001B (en) * | 2015-03-13 | 2018-04-06 | 山东艾孚特科技有限公司 | A kind of N, N ＇ carbonic acyl radicals are double（The dioxygen ethylene imine of 4 ethyl 2,3）Preparation method |
| BR112017021869A2 (en) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | substituted quinazoline compounds and methods of use thereof |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| CN104844580B (en) * | 2015-04-17 | 2017-10-20 | 中国药科大学 | Pyrimidines, its preparation method and medical usage |
| CN104774184A (en) * | 2015-04-17 | 2015-07-15 | 中国药科大学 | Alpha-cyano-alpha, beta-unsaturated amide compound and medical application thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (en) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Method for screening for inhibitors of RAS |
| MX2018005967A (en) | 2015-11-16 | 2018-08-29 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof. |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (en) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Inhibitor of KRAS G12C mutant protein |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| KR20180075228A (en) * | 2016-12-26 | 2018-07-04 | 한미약품 주식회사 | Novel Process and Intermediates for Preparing Thienopyrimidine Compound |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| JP2020521741A (en) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Compounds for the treatment of cancer and methods of their use |
| CN110831933A (en) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | Quinazoline derivatives as modulators of mutated KRAS, HRAS or NRAS |
| JP2021524835A (en) | 2018-04-05 | 2021-09-16 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | AXL Kinase Inhibitors and Their Use |
| US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CN116262758B (en) * | 2021-12-15 | 2025-02-28 | 上海博悦生物科技有限公司 | 7-Methylthiazolo[5,4-d]pyrimidine compounds, preparation methods and uses thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280580A (en) * | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | Thienopyrimidines and thienopyridine derivatives useful as anticancer agents |
| WO2003022852A2 (en) * | 2001-09-11 | 2003-03-20 | Smithkline Beecham Corporation | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| CN1509291A (en) * | 2001-05-14 | 2004-06-30 | ��˹��ŵ�� | Oxazolo-and-furopyrimidines and their use in medicaments against tumors |
| WO2006004658A2 (en) * | 2004-06-29 | 2006-01-12 | Amgen Inc. | Furanopyrimidines |
| WO2010054285A2 (en) * | 2008-11-10 | 2010-05-14 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| WO2010062038A2 (en) * | 2008-11-27 | 2010-06-03 | 한국과학기술연구원 | Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same |
-
2011
- 2011-11-03 CN CN201110342682.0A patent/CN103087077B/en active Active
-
2012
- 2012-10-31 WO PCT/CN2012/083830 patent/WO2013064068A1/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1280580A (en) * | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | Thienopyrimidines and thienopyridine derivatives useful as anticancer agents |
| CN1509291A (en) * | 2001-05-14 | 2004-06-30 | ��˹��ŵ�� | Oxazolo-and-furopyrimidines and their use in medicaments against tumors |
| WO2003022852A2 (en) * | 2001-09-11 | 2003-03-20 | Smithkline Beecham Corporation | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| WO2006004658A2 (en) * | 2004-06-29 | 2006-01-12 | Amgen Inc. | Furanopyrimidines |
| WO2010054285A2 (en) * | 2008-11-10 | 2010-05-14 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| WO2010062038A2 (en) * | 2008-11-27 | 2010-06-03 | 한국과학기술연구원 | Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103087077A (en) | 2013-05-08 |
| WO2013064068A1 (en) | 2013-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103087077B (en) | Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically | |
| CN103068391B (en) | Morpholinopyrimidines and their therapeutic uses | |
| CN101675053B (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use | |
| CN106132956B (en) | Heterocyclic compound, preparation method and application thereof | |
| CA2993096C (en) | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | |
| JP2022521901A (en) | A novel pyrido [3,4-D] pyrimidine-8-one derivative having a protein kinase inhibitory activity and a pharmaceutical composition containing the same for preventing, ameliorating or treating cancer. | |
| CN105209467A (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| CN102713618A (en) | Protein Kinase Complexes and Inhibitors | |
| CN105899490A (en) | Pyrimidine fgfr4 inhibitors | |
| CN105492009A (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
| CN111601807B (en) | Exo-azaspiro inhibitors of MENIN-MLL interactions | |
| CN103153300A (en) | Heteroaryls and uses thereof | |
| HK1210608A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| CN102971327B (en) | There is the anti-inflammatory compound of multiple tyrosine-kinase enzyme inhibition activity and the pharmaceutical compositions containing these compounds | |
| CN105315285A (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medical uses thereof | |
| CN117337193A (en) | combination therapy | |
| CN101921268B (en) | 5-thiazole amide compound and biological applications | |
| CN107417687A (en) | Five-ring heterocycles simultaneously [3,4 d] pyridazinone compound, its preparation method, pharmaceutical composition and its application | |
| WO2020156283A1 (en) | Alkynylpyrimidine or alkynylpyridine compound, and composition and application thereof | |
| CN104250252B (en) | Pyrazolo [1,5 a] pyrimidines and preparation method thereof and medical usage | |
| CN103360407B (en) | A kind of Thienopyrimidine analog derivative, its preparation method and in application pharmaceutically | |
| CN110407839A (en) | The preparation and application of the triazol heterocycle compound of the structure containing heteroaryl amide | |
| CN116239580A (en) | Triazine compound and its preparation method, pharmaceutical composition and application | |
| CN103373971B (en) | Urea compounds as protein kinase inhibitors | |
| WO2016041201A1 (en) | Thienopyrimidine derivatives and preparation method therefor and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180518 Address after: 213300 No. 3 Kang An Road, Liyang Economic Development Zone, Liyang, Jiangsu. Patentee after: Jiangsu Disainuo Pharmaceutical Co., Ltd. Address before: 201203 Zhang Heng road 3, 9, 3, Pudong New Area Road, Shanghai. Patentee before: Shanghai Ximai Medical Technology Co., Ltd. |